Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 03-06 July 2023

Chair: Sabine Straus – Vice-Chair: Martin Huber

03 July 2023, 10:30 – 19:45, via teleconference
04 July 2023, 08:30 – 19:45, via teleconference
05 July 2023, 08:30 – 19:45, via teleconference
06 July 2023, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)
20 July 2023, Time, 09:00 – 12:00, via teleconference

Health and safety information
In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006 Rev.1).
# Table of contents

## 1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts ........ 12
1.2. Agenda of the meeting on 03-06 July 2023 .............................................. 12
1.3. Minutes of the previous meeting on 05-08 June 2023 .............................. 12

## 2. EU referral procedures for safety reasons: urgent EU procedures 12

2.1. Newly triggered procedures ................................................................. 12
2.2. Ongoing procedures ........................................................................... 12
2.3. Procedures for finalisation ................................................................. 12

## 3. EU referral procedures for safety reasons: other EU referral procedures 12

3.1. Newly triggered procedures ................................................................. 12
3.2. Ongoing procedures ........................................................................... 12
3.3. Procedures for finalisation ................................................................. 13
3.4. Re-examination procedures .............................................................. 13
3.5. Others ................................................................................................. 13

## 4. Signals assessment and prioritisation 13

4.1. New signals detected from EU spontaneous reporting systems .......... 13
   4.1.1. Axicabtagene Ciloleucel – YESCARTA (CAP) ................................... 13
   4.1.2. Ixazomib – NINLARO (CAP) ............................................................ 13
   4.1.3. Liraglutide – SAXENDA (CAP), VICTOZA (CAP), XULTOPHY (CAP); Semaglutide – OZEMPIC (CAP), RYBELSUS (CAP), WEGOVY (CAP) ........................................ 14
   4.1.4. Liraglutide – SAXENDA (CAP), VICTOZA (CAP), XULTOPHY (CAP) ....... 14
   4.2. New signals detected from other sources ......................................... 14
   4.2.1. Dabrafenib - TAFINLAR (CAP); Trametinib - MEKINIST (CAP) .......... 14
   4.2.2. Encorafenib – BRAFTOVI (CAP); Binimetinib – MEKTOVI (CAP) ....... 14
   4.3. Signals follow-up and prioritisation ............................................... 15
   4.3.1. Olaparib - LYNPARZA (CAP) - EMEA/H/C/003726/SDA 021.1 .......... 15
   4.4. Variation procedure(s) resulting from signal evaluation .................. 15

## 5. Risk management plans (RMPs) 15

5.1. Medicines in the pre-authorisation phase ........................................... 15
   5.1.1. Lebrikizumab - EMEA/H/C/005894 .............................................. 15
   5.1.2. Leniolisib - EMEA/H/C/005927, Orphan ...................................... 15
   5.1.3. Natalizumab - EMEA/H/C/005752 .............................................. 15
   5.1.4. Palopegteriparatide - EMEA/H/C/005934, Orphan ...................... 15
   5.1.5. Pegzilarginase - EMEA/H/C/005484, Orphan ............................. 16
5.3.2. Rezafungin - EMEA/H/C/005900, Orphan ................................................................. 16
5.3.7. Trastuzumab duocarmazine - EMEA/H/C/005654 ...................................................... 16
5.3.18. Vamorolone - EMEA/H/C/005679, Orphan .............................................................. 16

5.2. Medicines in the post-authorisation phase – PRAC-led procedures .................. 16

5.2.1. Abiraterone acetate - ZYTIGA (CAP) - EMEA/H/C/002321/II/0072 ...................... 16
5.2.2. Anakinra - KINERET (CAP) - EMEA/H/C/000363/II/0090 .......................... 16
5.2.3. Benralizumab - FASENRA (CAP) - EMEA/H/C/004433/II/0049/G .................. 17
5.2.4. Esomeprazole - NEXIUM CONTROL (CAP) - EMEA/H/C/002618/II/0038 .......... 17
5.2.5. Insulin glargine - LANTUS (CAP) - EMEA/H/C/000284/WS2491/0127; TOUJEO (CAP) - EMEA/H/C/00309/WS2491/0122 ................................. 17
5.2.6. Miglustat - ZAVESCA (CAP) - EMEA/H/C/000435/II/0076 ............................. 17
5.2.7. Somatropin - NUTROPINAQ (CAP) - EMEA/H/C/000315/II/0077 ................. 18
5.2.8. Velaglucerase alfa - VPRIV (CAP) - EMEA/H/C/001249/II/0061 ...................... 18

5.3. Medicines in the post-authorisation phase – CHMP-led procedures ............ 18

5.3.1. Anifrolumab - SAPHNELO (CAP) - EMEA/H/C/004975/II/0007 .................... 18
5.3.2. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/II/0078 .................. 18
5.3.3. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/X/0076 ................. 19
5.3.4. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/II/0037 ......................... 19
5.3.5. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/X/0035/G ................... 19
5.3.7. Denosumab - PROLIA (CAP) - EMEA/H/C/001120/II/0098 ............................. 20
5.3.8. Dolutegravir, lamivudine - DOVATO (CAP) - EMEA/H/C/004909/II/0040/G ........ 20
5.3.9. Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/II/0023 ......................... 20
5.3.10. Efgartigimod alfa - VIVYGART (CAP) - EMEA/H/C/005849/II/0006, Orphan ..... 21
5.3.11. Efgartigimod alfa - VIVYGART (CAP) - EMEA/H/C/005849/X/0003, Orphan .... 21
5.3.13. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/II/0113 ........................... 22
5.3.14. Influenza vaccine (surface antigen, inactivated, adjuvanted) - FLUAD TETRA (CAP) - EMEA/H/C/004993/II/0043 .................................................. 22
5.3.15. Ivacaftor - KALYDECO (CAP) - EMEA/H/C/002494/X/0114/G ....................... 22
5.3.16. Ivacaftor, tezacaftor, exacaftor - KAFTRIO (CAP) - EMEA/H/C/005269/X/0033, Orphan . 23
5.3.17. Lanadelumab - TAKHZYRO (CAP) - EMEA/H/C/004806/X/0034/G, Orphan .......... 23
5.3.18. Maralixibat - LIVMARLI (CAP) - EMEA/H/C/005857/II/0003/G, Orphan ......... 23
5.3.19. Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/II/0136 ......................... 24
5.3.20. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/II/0043/G ....... 24
5.3.21. Nirsevimab - BEYFORTUS (CAP) - EMEA/H/C/005304/II/0005 ...................... 24
5.3.22. Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/II/0130 ........................... 25
5.3.23. Obinutuzumab - GAZYVARO (CAP) - EMEA/H/C/002799/II/0052, Orphan .......... 25
5.3.24. Olaparib - LYNPARZA (CAP) - EMEA/H/C/003726/II/0061 ............................ 25
6. **Periodic safety update reports (PSURs)**

6.1. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>EMA/PRAC Code</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1.1.</td>
<td>Aflibercept - EYLEA (CAP) - PSUSA/00010020/202211 ..........................................................</td>
<td>31</td>
</tr>
<tr>
<td>6.1.2.</td>
<td>Angiotensin II - GIAPREZA (CAP) - PSUSA/00010785/202212 .........................................................</td>
<td>31</td>
</tr>
<tr>
<td>6.1.3.</td>
<td>Artesunate - ARTESUNATE AMIVAS (CAP) - PSUSA/00010958/202212 ...................................................</td>
<td>31</td>
</tr>
<tr>
<td>6.1.4.</td>
<td>Atidarsagene autotemcel - LIBMELDY (CAP) - PSUSA/00010899/202212 ..............................................</td>
<td>31</td>
</tr>
<tr>
<td>6.1.5.</td>
<td>Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - STRIMVELIS (CAP) - PSUSA/00010505/202211 ................................................</td>
<td>32</td>
</tr>
<tr>
<td>6.1.6.</td>
<td>Berotralstat - ORLADEOY (CAP) - PSUSA/00010930/202212 ..............................................................</td>
<td>32</td>
</tr>
<tr>
<td>6.1.7.</td>
<td>Blinatumomab - BLINCYTO (CAP) - PSUSA/00010460/202212 ..............................................................</td>
<td>32</td>
</tr>
<tr>
<td>6.1.8.</td>
<td>Budesonide - KINPEYGO (CAP) - PSUSA/00011007/202212 .................................................................</td>
<td>32</td>
</tr>
<tr>
<td>6.1.9.</td>
<td>Buprenorphine - SIXMO (CAP) - PSUSA/00010778/202211 .................................................................</td>
<td>32</td>
</tr>
<tr>
<td>6.1.10.</td>
<td>Coronavirus (COVID-19) vaccine (recombinant, adjuvanted) - NUVAXOVID (CAP) - PSUSA/00010972/202212 ................................................</td>
<td>33</td>
</tr>
<tr>
<td>6.1.11.</td>
<td>Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - PSUSA/00010912/202212 ................................................</td>
<td>33</td>
</tr>
<tr>
<td>6.1.12.</td>
<td>Dengue tetravalent vaccine (live, attenuated) - DENGVAXIA (CAP) - PSUSA/00010740/202212 .....................</td>
<td>33</td>
</tr>
<tr>
<td>6.1.13.</td>
<td>Efgartigimod alfa - VYVGART (CAP) - PSUSA/00011014/202212 ........................................................</td>
<td>33</td>
</tr>
<tr>
<td>6.1.14.</td>
<td>Eladocogene exuparvovec - UPSTAZA (CAP) - PSUSA/00011004/202212 .................................................</td>
<td>33</td>
</tr>
<tr>
<td>6.1.15</td>
<td>Elasomeran (Spikevax), elasomeran, imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran, davesomeran (Spikevax bivalent Original/Omicron BA.4-5) - SPIKEVAX (CAP) - PSUSA/00010897/202212 (with RMP) ........................................................................................................... 34</td>
<td></td>
</tr>
<tr>
<td>6.1.16</td>
<td>Enfortumab vedotin - PADCEV (CAP) - PSUSA/00010989/202212 ......................................................................................................................... 34</td>
<td></td>
</tr>
<tr>
<td>6.1.17</td>
<td>Entrectinib - ROZLYTREK (CAP) - PSUSA/00010874/202212 ......................................................................................................................... 34</td>
<td></td>
</tr>
<tr>
<td>6.1.18</td>
<td>Fenfluramine - FINEPLA (CAP) - PSUSA/00010907/202212 ......................................................................................................................... 34</td>
<td></td>
</tr>
<tr>
<td>6.1.19</td>
<td>Formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - RILTRAVA AEROSPHERE (CAP); TRIXE AEROSPHERE (CAP) - PSUSA/00010908/202212 ......................................................................................................................... 34</td>
<td></td>
</tr>
<tr>
<td>6.1.20</td>
<td>Human papillomavirus vaccine (rDNA) - 2-valent - CERVARIX (CAP) - PSUSA/0009175/202211 ......................................................................................................................... 34</td>
<td></td>
</tr>
<tr>
<td>6.1.21</td>
<td>Hydroxocobalamin - CYANOKIT (CAP) - PSUSA/00010228/202211 ......................................................................................................................... 35</td>
<td></td>
</tr>
<tr>
<td>6.1.22</td>
<td>Indacaterol - HIROBRIZ BREEZHALER (CAP); ONBREZ BREEZHALER (CAP); OSLIF BREEZHALER (CAP) - PSUSA/0001730/202211 ......................................................................................................................... 35</td>
<td></td>
</tr>
<tr>
<td>6.1.23</td>
<td>Inebiluzumab - UPLIZNA (CAP) - PSUSA/00010996/202212 ......................................................................................................................... 35</td>
<td></td>
</tr>
<tr>
<td>6.1.24</td>
<td>Inotuzumab ozogamicin - BESPONSA (CAP) - PSUSA/00010659/202212 ......................................................................................................................... 35</td>
<td></td>
</tr>
<tr>
<td>6.1.25</td>
<td>Lorotrectinib - VITRAKVI (CAP) - PSUSA/00010799/202211 ......................................................................................................................... 35</td>
<td></td>
</tr>
<tr>
<td>6.1.26</td>
<td>Latanoprost, netarsudil - ROCLANDA (CAP) - PSUSA/00010905/202212 ......................................................................................................................... 36</td>
<td></td>
</tr>
<tr>
<td>6.1.27</td>
<td>Levodopa - INBRIJA (CAP) - PSUSA/00107800/202212 ......................................................................................................................... 36</td>
<td></td>
</tr>
<tr>
<td>6.1.28</td>
<td>Luspatercept - REBLOZYL (CAP) - PSUSA/00010860/202212 ......................................................................................................................... 36</td>
<td></td>
</tr>
<tr>
<td>6.1.29</td>
<td>Lutetium (177Lu) oxodotreotide - LUTATHERA (CAP) - PSUSA/00010643/202212 ......................................................................................................................... 36</td>
<td></td>
</tr>
<tr>
<td>6.1.30</td>
<td>Lutropin alfa - LUVERIS (CAP) - PSUSA/0001918/202211 ......................................................................................................................... 36</td>
<td></td>
</tr>
<tr>
<td>6.1.31</td>
<td>Mexiletine - NAMUSCLA (CAP) - PSUSA/00010738/202212 ......................................................................................................................... 36</td>
<td></td>
</tr>
<tr>
<td>6.1.32</td>
<td>Mosunetuzumab - LUNSUMIO (CAP) - PSUSA/00010999/202212 ......................................................................................................................... 37</td>
<td></td>
</tr>
<tr>
<td>6.1.33</td>
<td>Obeticholic acid - OCALIVA (CAP) - PSUSA/0001555/202211 ......................................................................................................................... 37</td>
<td></td>
</tr>
<tr>
<td>6.1.34</td>
<td>Olaparib - LYNPARZA (CAP) - PSUSA/00010322/202212 ......................................................................................................................... 37</td>
<td></td>
</tr>
<tr>
<td>6.1.35</td>
<td>Pegvisomant - SOMAVENT (CAP) - PSUSA/0002328/202211 ......................................................................................................................... 37</td>
<td></td>
</tr>
<tr>
<td>6.1.36</td>
<td>Pertuzumab, trastuzumab - PHERGO (CAP) - PSUSA/00010906/202212 ......................................................................................................................... 37</td>
<td></td>
</tr>
<tr>
<td>6.1.37</td>
<td>Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - APEXXNAR (CAP) - PSUSA/00010981/202212 ......................................................................................................................... 38</td>
<td></td>
</tr>
<tr>
<td>6.1.38</td>
<td>Relugolix, estradiol, norethisterone acetate - RYEQO (CAP) - PSUSA/00010942/202211 ......................................................................................................................... 38</td>
<td></td>
</tr>
<tr>
<td>6.1.39</td>
<td>Roxadustat - EVRENZ (CAP) - PSUSA/00010955/202212 ......................................................................................................................... 38</td>
<td></td>
</tr>
<tr>
<td>6.1.40</td>
<td>Rucaparib - RUBRACA (CAP) - PSUSA/00010694/202212 ......................................................................................................................... 38</td>
<td></td>
</tr>
<tr>
<td>6.1.41</td>
<td>Satralizumab - ENSPRYNG (CAP) - PSUSA/00010944/202211 ......................................................................................................................... 38</td>
<td></td>
</tr>
<tr>
<td>6.1.42</td>
<td>Sotorasib - LUMYKRAS (CAP) - PSUSA/00010970/202211 ......................................................................................................................... 38</td>
<td></td>
</tr>
<tr>
<td>6.1.43</td>
<td>Tagraxofusp - ELZONRIS (CAP) - PSUSA/00010896/202212 ......................................................................................................................... 39</td>
<td></td>
</tr>
<tr>
<td>6.1.44</td>
<td>Tezepelumab - TEZSPIRE (CAP) - PSUSA/00011015/202212 ......................................................................................................................... 39</td>
<td></td>
</tr>
<tr>
<td>6.1.45</td>
<td>Tirbanibulin - KLISYRI (CAP) - PSUSA/00010943/202212 ......................................................................................................................... 39</td>
<td></td>
</tr>
<tr>
<td>6.1.46</td>
<td>Tozinameran (COMIRNATY), tozinameran, riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran, fantozinameran (COMIRNATY Original/Omicron BA.4-5) - COMIRNATY (CAP) - PSUSA/00010898/202212 ......................................................................................................................... 39</td>
<td></td>
</tr>
<tr>
<td>6.1.47</td>
<td>Tralokinumab - ADTRALZA (CAP) - PSUSA/00010937/202212 ......................................................................................................................... 39</td>
<td></td>
</tr>
</tbody>
</table>
6.1.48. Trastuzumab deruxtecan - ENHERTU (CAP) - PSUSA/00010894/202212 ........................................ 40
6.1.49. Turoctocog alfa pegol - ESPEROCT (CAP) - PSUSA/00010782/202212 ........................................ 40
6.1.50. Vutrisiran - AMVUTTRA (CAP) - PSUSA/00011021/202212 ...................................................... 40

6.2. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs) ........................................ 40**

6.2.1. Acetylsalicylic acid, clopidogrel, clopidogrel - CLOPIDOGREL ZENTIVA (CAP); DUOPLAVIN (CAP); ISCOVER (CAP); PLAVIX (CAP) - NAP - PSUSA/00000820/202211 ........................................ 40
6.2.2. Docetaxel - TAXOTERE (CAP) - NAP - PSUSA/00001152/202211 ........................................ 40
6.2.3. Edotreotide - SOMAKIT TOC (CAP) - NAP - PSUSA/00010552/202212 ........................................ 41

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only ......................................................... 41**

6.3.1. Alfuzosin (NAP) - PSUSA/00000084/202211 ........................................................................ 41
6.3.2. Amlodipine (NAP), indapamide, amlodipine (NAP), indapamide (NAP), perindopril (NAP) - PSUSA/00010358/202211 ........................................ 41
6.3.3. Apomorphine (NAP) - PSUSA/00000227/202211 ................................................................. 41
6.3.4. Bacillus clausii multi-antibioresistant spores (NAP) - PSUSA/00000284/202211 ............... 41
6.3.5. Bambuterol (NAP) - PSUSA/00000295/202212 ................................................................. 42
6.3.6. Bromperidol (NAP) - PSUSA/00000439/202211 ................................................................. 42
6.3.7. Brotizolam (NAP) - PSUSA/00000444/202212 ................................................................. 42
6.3.8. Caffeine, ergotamine (NAP) - PSUSA/00000485/202211 ...................................................... 42
6.3.9. Cetirizine (NAP) - PSUSA/00000628/202211 ................................................................. 42
6.3.10. Dienogest (NAP) - PSUSA/00003167/202212 ................................................................. 42
6.3.11. Dutasteride (NAP), dutasteride, tamsulosine (NAP) - PSUSA/00010506/202211 ............... 43
6.3.12. Econazole (NAP), econazole nitrate, triamcinolone acetonide (NAP), econazole nitrate, zinc oxide (NAP) - PSUSA/00001195/202211 ........................................... 43
6.3.13. Flurbiprofen (NAP) - PSUSA/00001450/202211 ................................................................. 43
6.3.14. Horse-derived anti-T lymphocyte immunoglobulin for human use (NAP) - PSUSA/00010433/202211 ......................................................... 43
6.3.15. Hydroxycarbamide (NAP) - PSUSA/00009182/202212 ....................................................... 43
6.3.16. Idarubicin (NAP) - PSUSA/00001720/202211 ................................................................. 44
6.3.17. Inactivated leptospire vaccine (NAP) - PSUSA/00010813/202211 ........................................ 44
6.3.18. Lamotrigine (NAP) - PSUSA/00001825/202211 ................................................................. 44
6.3.19. Levocabastine (NAP) - PSUSA/00001849/202211 ................................................................. 44
6.3.20. Mizolastine (NAP) - PSUSA/00002078/202211 ................................................................. 44
6.3.21. Naltrexone (NAP) - PSUSA/00002117/202211 ................................................................. 44
6.3.22. Propofol (NAP) - PSUSA/00002555/202211 ................................................................. 45
6.3.23. Rosuvastatin (NAP) - PSUSA/00002664/202211 ................................................................. 45
6.3.24. Sodium fluoride (\(^{18}\)F) (NAP) - PSUSA/00010706/202211 ....................................................... 45
6.3.25. Yellow fever vaccine (live) (NAP) - PSUSA/00003135/202212 ........................................... 45

6.4. **Follow-up to PSUR/PSUSA procedures ................................................................. 45**
7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)

7.1.1. Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/PSA/S/0102.2 ................................... 46
7.1.2. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/PSA/S/0093.2 ......................................... 47
7.1.3. Valproate (NAP) - EMEA/H/N/PSP/J/0074.7 ................................................................. 47

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)

7.2.1. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/MEA 015 ................................... 47
7.2.2. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/MEA 016 ................................... 47
7.2.3. Coronavirus (COVID-19) vaccine (recombinant, adjuvanted) - NUVAXOVID (CAP) - EMEA/H/C/005808/MEA 004.3 ....................................... 48
7.2.4. Daridorexant - QUVIVIQ (CAP) - EMEA/H/C/005634/MEA 003 ..................................... 48
7.2.5. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/MEA 002.1 .................... 48
7.2.6. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/MEA 004.1 .................... 48
7.2.7. Fremanezumab - AJOVY (CAP) - EMEA/H/C/004833/MEA 003.3 ......................... 49
7.2.8. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/MEA 008.1 ........... 49
7.2.9. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/MEA 009.2 ........... 49
7.2.10. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/MEA 005.6 ......................... 49
7.2.11. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.6 .................... 49
7.2.12. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.6 .................... 50
7.2.13. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.4 .................... 50
7.2.14. Talimogene laherparepvec - IMLYGIC (CAP) - EMEA/H/C/002771/MEA 005.2 .... 50
7.2.15. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 017.3 ......................... 50
7.2.16. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 014.3 ......................... 51

7.3. Results of PASS imposed in the marketing authorisation(s)

7.3.1. Trasylol (NAP) - EMEA/H/N/PSR/S/0030 ................................................................. 51
7.3.2. Valproate (NAP) - EMEA/H/N/PSR/J/0043 ............................................................. 51

7.4. Results of PASS non-imposed in the marketing authorisation(s)

7.4.1. Agalsidase alfa - REPLAGAL (CAP) - EMEA/H/C/000369/II/0126 ...................... 52
7.4.2. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/II/0061, Orphan .................... 52
7.4.3. Eribulin - HALAVEN (CAP) - EMEA/H/C/002084/II/0067 ................................ 52
7.4.4. Etelcalcetide - PARSABIV (CAP) - EMEA/H/C/003995/II/0021 ......................... 53
7.4.5. Gilteritinib - XOSPATA (CAP) - EMEA/H/C/004752/II/0012, Orphan ............... 53
7.4.6. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0241 ......................... 53
8.3.3. Pegfilgrastim - NEULASTA (CAP) - EMEA/H/C/000420/II/0121 ........................................ 53
8.3.2. Tezacaftor, ivacafator - SYMEVI (CAP) - EMEA/H/C/004682/II/0039, Orphan ................. 54
8.3.1. Vedolizumab - ENTYVIO (CAP) - EMEA/H/C/002782/II/0073 ........................................ 54
8.3. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation ................................................................. 54
8.3.1. Ataluren - TRANSLARNA (CAP) - EMEA/H/C/002720/MEA 002.9 ................................. 54
8.3.2. Cabazitaxel - CABAZITAXEL ACCORD (CAP) - EMEA/H/C/005178/MEA 001.4 .......... 54
8.3.3. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 004.9 ................................. 54
8.3.4. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 034.6 ............................... 55
8.3.5. Fenfluramine - FINTEPLA (CAP) - EMEA/H/C/003933/MEA 002.2 ............................ 55
8.3.6. Nonacog beta pegol - REFIXIA (CAP) - EMEA/H/C/004178/LEG 006.4 ........................ 55
8.3.7. Tolvaptan - JINARC (CAP) - EMEA/H/C/002788/ANX 002.4 ....................................... 55
8.3.8. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 017.6 .......................... 56
8.3.9. Ulipristal acetate - ESMYA (CAP) - EMEA/H/C/002041/MEA 018.7 ............................ 56
8.3.10. Venetoclax - VENCLYXTO (CAP) - EMEA/H/C/004106/MEA 002.10 ........................ 56
8.3.11. Voretigene neparvovec - LUXTURNA (CAP) - EMEA/H/C/004451/ANX 011 .................. 57
8.6. Others ............................................................................................................................... 57
8.7. New Scientific Advice ....................................................................................................... 57
8.8. Ongoing Scientific Advice .................................................................................................. 57
8.9. Final Scientific Advice (Reports and Scientific Advice letters) ........................................ 57

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 57

8.1. Annual reassessments of the marketing authorisation ....................................................... 57
8.1.1. Amifampridine - FIRDAPSE (CAP) - EMEA/H/C/001032/S/0075 (without RMP) .......... 57
8.1.2. Chenodeoxycholic acid - CHENODEOXYCHOLIC ACID LEADIANT (CAP) - EMEA/H/C/004061/S/0022 (without RMP) .................................................. 57
8.1.3. Idursulfase - ELAPRASE (CAP) - EMEA/H/C/000700/S/0111 (without RMP) ............... 58
8.1.4. Tecovirimat - TECOVIRIMAT SIGA (CAP) - EMEA/H/C/005248/S/0004 (without RMP) .... 58
8.1.5. Zanamivir - DECTOVA (CAP) - EMEA/H/C/004102/S/0016 (without RMP) ................. 58
8.2. Conditional renewals of the marketing authorisation ......................................................... 58
8.2.1. Amivantamab - RYBREVANT (CAP) - EMEA/H/C/005454/R/0007 (without RMP) ...... 58
8.2.2. Ixazomib - NINLARO (CAP) - EMEA/H/C/003844/R/0043 (without RMP) ............... 58
8.2.3. Pralsetinib - GAVRETO (CAP) - EMEA/H/C/005413/R/0014 (without RMP) .............. 59
8.2.4. Spesolimab - SPEVIGO (CAP) - EMEA/H/C/005874/R/0005 (without RMP) ............... 59
8.3. Renewals of the marketing authorisation ........................................................................... 59
8.3.1. Apalutamide - ERLEADA (CAP) - EMEA/H/C/004452/R/0030 (with RMP) ............... 59
8.3.2. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/R/0083 (without RMP) .. 59
8.3.3. Galcanezumab - EMGALITY (CAP) - EMEA/H/C/004648/R/0023 (with RMP) .......... 59
8.3.4. Glycopyrronium, formoterol fumarate dihydrate - BEVESPI AEROSPHERE (CAP) - EMEA/H/C/004245/R/0017 (without RMP) ................................................................. 59
8.3.5. Lidocaine, prilocaine - FORTACIN (CAP) - EMEA/H/C/002693/R/0038 (without RMP) ....... 60
8.3.6. Paclitaxel - APEALEA (CAP) - EMEA/H/C/004154/R/0017 (with RMP) .......................... 60
8.3.7. Pegfilgrastim - FULPHILA (CAP) - EMEA/H/C/004915/R/0042 (without RMP) ............... 60
8.3.8. Radium (Ra$^{223}$) - XOFIGO (CAP) - EMEA/H/C/002653/R/0049 (with RMP) .......... 60
8.3.9. Ropeginterferon alfa-2b - BESREMI (CAP) - EMEA/H/C/004128/R/0031 (without RMP) .... 60
8.3.10. Silodosin - SILODOSIN RECORDATI (CAP) - EMEA/H/C/004964/R/0012 (without RMP) ....... 61
8.3.11. Tobramycin - VANTOBRA (CAP) - EMEA/H/C/005086/R/0009 (without RMP) ........... 61

9. Product related pharmacovigilance inspections 61

9.1. List of planned pharmacovigilance inspections ................................................................. 61
9.2. Ongoing or concluded pharmacovigilance inspections .................................................... 61
9.3. Others ............................................................................................................................... 61

10. Other safety issues for discussion requested by the CHMP or the EMA 61

10.1. Safety related variations of the marketing authorisation .................................................... 61
10.2. Timing and message content in relation to Member States’ safety announcements 61
10.3. Other requests .................................................................................................................. 62
10.4. Scientific Advice ............................................................................................................. 62

11. Other safety issues for discussion requested by the Member States 62

11.1. Safety related variations of the marketing authorisation .................................................... 62
11.1.1. Amino acid combinations, glucose, triglyceride combinations, with or without electrolytes, mineral compounds (NAP) - SE/H/918/02-04/II/51 ................................................... 62
11.2. Other requests .................................................................................................................. 62

12. Organisational, regulatory and methodological matters 62

12.1. Mandate and organisation of the PRAC ............................................................................. 62
12.1.1. PRAC membership ........................................................................................................ 62
12.1.2. Vote by proxy .................................................................................................................. 62
12.1.3. Scientific Committee Meetings – alternating face-to-face and virtual meetings schedule for 2024 .............................................................................................................. 62
12.2. Coordination with EMA Scientific Committees or CMDh-v ............................................. 63
12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ................. 63
12.4. Cooperation within the EU regulatory network ................................................................. 63
12.4.1. Coronavirus (COVID-19) pandemic - update ................................................................ 63
12.5. Cooperation with International Regulators ........................................................................ 63
12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee ............................................................................................................. 63
12.7. PRAC work plan ................................................................................................................ 63
12.8. Planning and reporting ................................................................. 63
12.8.1. Marketing authorisation applications (MAA) forecast for 2023 – planning update dated Q2 2023 ................................................................. 63
12.9. Pharmacovigilance audits and inspections ......................................... 63
12.9.1. Pharmacovigilance systems and their quality systems .......................... 63
12.9.2. Pharmacovigilance inspections ..................................................... 64
12.9.3. Pharmacovigilance audits .......................................................... 64
12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list ........ 64
12.10.1. Periodic safety update reports ...................................................... 64
12.10.2. Granularity and Periodicity Advisory Group (GPAG) ......................... 64
12.10.3. PSURs repository ........................................................................ 64
12.10.4. Union reference date list – consultation on the draft list .................... 64
12.10.5. Periodic Safety Update Reports Single Assessment (PSUSA) – proactive publication of PRAC assessment reports for COVID-19 vaccines .......................... 64
12.11. Signal management ................................................................. 64
12.11.2. Signal management – List of substances subject to worksharing ............ 64
12.12. Adverse drug reactions reporting and additional reporting ...................... 65
12.12.1. Management and reporting of adverse reactions to medicinal products ................................................................. 65
12.12.2. Additional monitoring ............................................................... 65
12.12.3. List of products under additional monitoring – consultation on the draft list ................................................................. 65
12.13. EudraVigilance database ............................................................. 65
12.13.1. Activities related to the confirmation of full functionality ...................... 65
12.14.1. Risk management systems .......................................................... 65
12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations .... 65
12.15. Post-authorisation safety studies (PASS) ............................................ 65
12.15.1. Post-authorisation Safety Studies – imposed PASS ............................ 65
12.15.2. Post-authorisation Safety Studies – non-imposed PASS ....................... 65
12.16. Community procedures ............................................................ 66
12.16.1. Referral procedures for safety reasons ............................................. 66
12.17. Renewals, conditional renewals, annual reassessments ............................ 66
12.18. Risk communication and transparency ............................................. 66
12.18.1. Public participation in pharmacovigilance ....................................... 66
12.18.2. Safety communication .............................................................. 66
12.19. Continuous pharmacovigilance ...................................................... 66
12.19.1. Incident management ............................................................... 66
12.20. Impact of pharmacovigilance activities ............................................ 66
12.20.1. Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines in context of thrombosis with thrombocytopenia syndrome (TTS): risk awareness and adherence - PRAC Sponsor’s critical appraisal ................................................................. 66

12.20.2. Strategy on measuring the impact of pharmacovigilance – PRAC interest group (IG) Impact – revision of the process for prioritisation and follow-up of impact research, including regulatory toolbox (rev.2) ................................................................. 66

12.21. **Others** ........................................................................................................................................ 67

12.21.1. International Conference on Harmonisation (ICH) E2D(R1) guideline - Post-approval safety data management: definitions and standards for expedited reporting – update on the revision process ......................................................................................... 67

12.21.2. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling – concept paper on revision of the guideline ......................................................... 67

12.21.3. Good Pharmacovigilance Practice (GVP) – mid-year update 2023........................................ 67

12.21.4. EMA-funded study on anticonvulsants in pregnancy ........................................................................ 67

12.21.5. PRAC Assessors trainings - EU NTC Learning & Development (L&D) toolkit and remuneration for training development/delivery ...................................................................................................... 67

13. **Any other business** .................................................................................................................................. 67

14. **Explanatory notes** .................................................................................................................................... 68
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 03-06 July 2023. See July 2023 PRAC minutes (to be published post September 2023 PRAC meeting).

1.2. **Agenda of the meeting on 03-06 July 2023**

*Action: For adoption*

1.3. **Minutes of the previous meeting on 05-08 June 2023**

*Action: For adoption*

2. **EU referral procedures for safety reasons: urgent EU procedures**

2.1. **Newly triggered procedures**

None

2.2. **Ongoing procedures**

None

2.3. **Procedures for finalisation**

None

3. **EU referral procedures for safety reasons: other EU referral procedures**

3.1. **Newly triggered procedures**

None

3.2. **Ongoing procedures**

None
3.3. Procedures for finalisation
None

3.4. Re-examination procedures
None

3.5. Others
None

4. Signals assessment and prioritisation

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Axicabtagene Ciloleucel – YESCARTA (CAP)

Applicant: Kite Pharma EU B.V., ATMP
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Signal of progressive multifocal leukoencephalopathy (PML)
Action: For adoption of PRAC recommendation
EPITT 19940 – New signal
Lead Member State(s): DK

4.1.2. Ixazomib – NINLARO (CAP)

Applicant: Takeda Pharma A/S
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Signal of angioedema and anaphylactic reaction
Action: For adoption of PRAC recommendation
EPITT 19950 – New signal
Lead Member State(s): SE

---

1 Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
2 Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required
3 Advanced therapy medicinal product
4.1.3. **Liraglutide –** SAXENDA (CAP), VICTOZA (CAP), XULTOPHY (CAP); **Semaglutide –** OZEMPIC (CAP), RYBELSUS (CAP), WEGOVY (CAP)

Applicant: Novo Nordisk A/S

PRAC Rapporteur: to be appointed

Scope: Signal of suicidal ideation and self-injurious ideation

**Action:** For adoption of PRAC recommendation

EPITT 19946 – New signal

Lead Member State(s): NL

4.1.4. **Liraglutide –** SAXENDA (CAP), VICTOZA (CAP), XULTOPHY (CAP)

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Menno van der Elst

Scope: Signal of drug-induced liver injury

**Action:** For adoption of PRAC recommendation

EPITT 19949 – New signal

Lead Member State(s): NL

4.2. **New signals detected from other sources**

4.2.1. **Dabrafenib –** TAFINLAR (CAP); **Trametinib –** MEKINIST (CAP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: to be appointed

Scope: Signal of peripheral neuropathy

**Action:** For adoption of PRAC recommendation

EPITT 19947 – New signal

Lead Member State(s): NO

4.2.2. **Encorafenib –** BRAFTOVI (CAP); **Binimetinib –** MEKTOVI (CAP)

Applicant: Pierre Fabre Medicament

PRAC Rapporteur: to be appointed

Scope: Signal of tumour lysis syndrome

**Action:** For adoption of PRAC recommendation

EPITT 19941 – New signal

Lead Member State(s): PT
4.3. **Signals follow-up and prioritisation**

4.3.1. **Olaparib - LYNPARZA (CAP) - EMEA/H/C/003726/SDA 021.1**

   Applicant: AstraZeneca AB
   PRAC Rapporteur: Amelia Cupelli
   Scope: Signal of hepatocellular damage and hepatitis (HLT)
   **Action:** For adoption of PRAC recommendation
   EPITT 19846 – Follow-up to March 2023

4.4. **Variation procedure(s) resulting from signal evaluation**

   None

5. **Risk management plans (RMPs)**

5.1. **Medicines in the pre-authorisation phase**

5.1.1. **Lebrikizumab - EMEA/H/C/005894**

   Scope: Treatment of moderate-to-severe atopic dermatitis in adults and adolescents
   **Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. **Leniolisib - EMEA/H/C/005927, Orphan**

   Applicant: Pharming Technologies B.V.
   Scope: Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)
   **Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. **Natalizumab - EMEA/H/C/005752**

   Scope: Treatment of active relapsing remitting multiple sclerosis (RRMS)
   **Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. **Palopegteriparatide - EMEA/H/C/005934, Orphan**

   Applicant: Ascendis Pharma Bone Diseases A/S
   Scope: Parathyroid replacement therapy indicated for the treatment of hypoparathyroidism in adults
   **Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.1.5. Pegzilarginase - EMEA/H/C/005484, Orphan

Applicant: Immedica Pharma AB
Scope: Treatment of hyperargininemia
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Rezafungin - EMEA/H/C/005900, Orphan

Applicant: Mundipharma GmbH
Scope: Treatment of invasive candidiasis
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. Trastuzumab duocarmazine - EMEA/H/C/005654

Scope: Treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast cancer
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Vamorolone - EMEA/H/C/005679, Orphan

Applicant: Santhera Pharmaceuticals (Deutschland) GmbH
Scope: Treatment of Duchenne muscular dystrophy (DMD)
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Abiraterone acetate - ZYTIGA (CAP) - EMEA/H/C/002321/II/0072

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Submission of an updated RMP version 15.1 in order to align with Good Pharmacovigilance Practices Module V, Revision 2
Action: For adoption of PRAC Assessment Report

5.2.2. Anakinra - KINERET (CAP) - EMEA/H/C/000363/II/0090

Applicant: Swedish Orphan Biovitrum AB (publ)
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Submission of an updated RMP version 6.2 in order to add DRESS as an important potential risk as well as the removal of the additional risk minimization measures for serious infections, following the assessment of procedure PSUSA/00000209/202205. Annexes II and IV are updated in accordance
**Action:** For adoption of PRAC Assessment Report

### 5.2.3. Benralizumab - FASENRA (CAP) - EMEA/H/C/004433/II/0049/G

**Applicant:** AstraZeneca AB

**PRAC Rapporteur:** David Olsen

**Scope:** Grouped application consisting of: 1) Submission of an updated RMP version 5 in order to remove the safety concern of missing information on use in pregnant and lactating women. Consequently, the MAH proposes to remove study D3250R00026 as an additional pharmacovigilance activity, and to remove the commitment to conduct additional pharmacovigilance for the use of benralizumab in pregnant and lactating women with severe eosinophilic asthma; 2) Submission of an updated RMP version 5 in order to remove the safety concern of important potential risk of serious infections

**Action:** For adoption of PRAC Assessment Report

### 5.2.4. Esomeprazole - NEXIUM CONTROL (CAP) - EMEA/H/C/002618/II/0038

**Applicant:** GlaxoSmithKline Dungarvan Ltd

**PRAC Rapporteur:** Rugile Pilviniene

**Scope:** Submission of an updated RMP version 2.0 in order to update the list of safety concerns to meet the definition of important risk and missing information provided in GVP Module V Rev. 2

**Action:** For adoption of PRAC Assessment Report

### 5.2.5. Insulin glargine - LANTUS (CAP) - EMEA/H/C/000284/WS2491/0127; TOUJEO (CAP) - EMEA/H/C/000309/WS2491/0122

**Applicant:** Sanofi-Aventis Deutschland GmbH

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Submission of an updated RMP version 7.0 of Toujeo and Lantus following removal of the "Medication error due to non-compliance with instructions to use a new needle for each injection: wrong dose injected due to blocked needle" from the list of safety concerns (EMEA/H/C/000309/II/0105/G), to: remove the follow-up questionnaire for the topic "Medication error due to non-compliance with instructions to use a new needle for each injection: wrong dose injected due to blocked needle" from routine pharmacovigilance activities (Part III); remove the suspected blockage of needle questionnaire (Annex 4); update with the revised data lock point (DLP) (Part II)

**Action:** For adoption of PRAC Assessment Report

### 5.2.6. Miglustat - ZAVESCA (CAP) - EMEA/H/C/000435/II/0076

**Applicant:** Janssen-Cilag International N.V.

**PRAC Rapporteur:** Mari Thorn

**Scope:** Submission of an updated RMP version 15.1 in order to remove risks in line with GVP
module V revision 2. The MAH has also taken the opportunity to introduce minor changes, such as update of the post marketing exposure data and alignment with the latest Company EU-RMP Template.

**Action:** For adoption of PRAC Assessment Report

### 5.2.7. Somatropin - NUTROPINAQ (CAP) - EMEA/H/C/000315/II/0077

**Applicant:** Ipsen Pharma  
**PRAC Rapporteur:** Marie Louise Schougaard Christiansen  
**Scope:** Submission of an updated RMP version 4.0 in order to remove some of the safety concerns in compliance with GVP Module V Revision 2. In addition, the MAH took the opportunity to add data from final clinical study report of International Cooperative Growth Study (iNCGS) registry (non-interventional study) and exposure and safety information.  
**Action:** For adoption of PRAC Assessment Report

### 5.2.8. Velaglucerase alfa - VPRIV (CAP) - EMEA/H/C/001249/II/0061

**Applicant:** Takeda Pharmaceuticals International AG Ireland Branch  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Submission of an updated RMP version 12 in order to remove certain risks from the list of safety concerns.  
**Action:** For adoption of PRAC Assessment Report

### 5.3. Medicines in the post-authorisation phase – CHMP-led procedures

#### 5.3.1. Anifrolumab - SAPHNELO (CAP) - EMEA/H/C/004975/II/0007

**Applicant:** AstraZeneca AB  
**PRAC Rapporteur:** Liana Gross-Martirosyan  
**Scope:** Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC based on final results from study D3461C00009 listed as an additional pharmacovigilance activity in the RMP; this is a multicentre, randomised, double-blind, placebo-controlled Phase III extension study to characterise the long-term safety and tolerability of anifrolumab in adult subjects with active systemic lupus erythematosus. In addition, the MAH took the opportunity to implement minor changes to sections 4.2 and 6.6 of the SmPC and to the package leaflet.  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.2. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/II/0078

**Applicant:** Roche Registration GmbH  
**PRAC Rapporteur:** Inês Ribeiro-Vaz  
**Scope:** Update of section 5.1 of the SmPC in order to include the final overall survival (OS).
analysis results based on final results from study WO30070 listed as a PAES in the Annex II to fulfil ANX/PAE 003; this is a Phase III, multicenter, randomised, placebo-controlled study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma. The RMP version 27 has also been submitted. In addition, the MAH took the opportunity to update Annex II of the SmPC

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.3. Atezolizumab - TECENTRIQ (CAP) - EMEA/H/C/004143/X/0076

**Applicant:** Roche Registration GmbH

**PRAC Rapporteur:** Inês Ribeiro-Vaz

**Scope:** Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (1875 mg) and new route of administration (subcutaneous use). The RMP (version 24.0) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.4. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/II/0037

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Adam Przybylkowski

**Scope:** Extension of indication to include the treatment of paediatric patients (from 2 years of age and older) with moderate to severe atopic dermatitis for OLUMIANT, based on the final results from study I4V-MC-JAIP; this is a Phase III, multicentre, randomised, double blind, placebo controlled, parallel-group, outpatient study evaluating the pharmacokinetics, efficacy, and safety of baricitinib in paediatric patients with moderate-to-severe atopic dermatitis. As a consequence sections 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1, 5.2 of the SmPC are updated. The package leaflet has been updated accordingly. Version 17.1 of the RMP has also been submitted.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.5. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/X/0035/G

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Adam Przybylkowski

**Scope:** Extension application to introduce a new strength (1 mg film-coated tablet), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment, as monotherapy or in combination with conventional synthetic disease modifying antirheumatic drugs (DMARDs), of active juvenile idiopathic arthritis (JIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs, based on final results from the pivotal study JAHV (I4V-MC-JAHV); this is a multicentre, double-blind, randomised, placebo-controlled, medication-withdrawal Phase 3 study in children from 2 years to less than 18 years of age with JIA who have had an inadequate response or intolerance to treatment with at least 1 conventional DMARD (cDMARD) or biological (bDMARD). As a consequence, sections 4.1,
4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. Version 15.1 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.6. Burosumab - CRYSVITA (CAP) - EMEA/H/C/004275/II/0035/G, Orphan

**Applicant:** Kyowa Kirin Holdings B.V.

**PRAC Rapporteur:** Gabriele Maurer

**Scope:** Grouped variation consisting of: 1) Addition of prefilled syringe presentation for the 10 mg strength; addition of prefilled syringe presentation for the 20 mg strength; addition of prefilled syringe presentation for the 30 mg strength; 2) other quality variations

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.7. Denosumab - PROLIA (CAP) - EMEA/H/C/001120/II/0098

**Applicant:** Amgen Europe B.V.

**PRAC Rapporteur:** Mari Thorn

**Scope:** Update of sections 4.2, 4.4, 5.1 and 5.2 in order to update efficacy, pharmacokinetic and safety information for paediatric population following the assessment of P46/043 and P46/044 based on final results from study 20130173, listed as a category 3 study in the RMP and study 20170534. Study 20130173 was a prospective, multicentre, open-label, single-arm phase 3 study to evaluate the safety, efficacy, and PK of denosumab in children 2 to 17 years of age with osteogenesis imperfecta (OI). Study 20170534 was an open-label, prospective, extension study of Study 20130173. The RMP version 31 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.8. Dolutegravir, lamivudine - DOVATO (CAP) - EMEA/H/C/004909/II/0040/G

**Applicant:** ViiV Healthcare B.V.

**PRAC Rapporteur:** David Olsen

**Scope:** Submission of the final reports from study 204861 (GEMINI-1) and study 205543 (GEMINI-2) listed as category 3 studies in the RMP; these are phase 3, randomised, double-blind, multicentre, parallel group, non-inferiority studies evaluating the efficacy, safety and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naive adults. The RMP version 4.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.9. Dostarlimab - JEMPERLI (CAP) - EMEA/H/C/005204/II/0023

**Applicant:** GlaxoSmithKline (Ireland) Limited

**PRAC Rapporteur:** Inês Ribeiro-Vaz
Scope: Extension of indication to include in combination with platinum-containing chemotherapy the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy, based on results from study 213361 (RUBY) Part 1, listed as a Specific Obligation in the Annex II; this is a phase 3, randomised, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and package leaflet are updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the product information. As part of the application, the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

**5.3.10. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/II/0006, Orphan**

Applicant: Argenx

PRAC Rapporteur: Rhea Fitzgerald

Scope: Update of sections 4.4 and 4.5 of the SmPC in order to amend an existing warning on use of vaccination and update drug-drug interaction information on vaccines based on final results from study ARGX-113-2102; this is a phase 1, randomised, open-label, placebo-controlled, parallel-group study to evaluate the immune response to PNEUMOVAX 23 in healthy participants receiving efgartigimod IV 10 mg/kg or placebo. The RMP version 1.2 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

**5.3.11. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/X/0003, Orphan**

Applicant: Argenx

PRAC Rapporteur: Rhea Fitzgerald

Scope: Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (1000 mg) and a new route of administration (subcutaneous use)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

**5.3.12. Fluticasone furoate, vilanterol - RELVAR ELLIPTA (CAP) - EMEA/H/C/002673/WS2438/0061/G; REVINITY ELLIPTA (CAP) - EMEA/H/C/002745/WS2438/0058/G**

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Monica Martinez Redondo

Scope: Grouped application consisting of 1) Update sections 4.2 and 5.1 of the SmPC to include results from study HZA107116. This is a randomised, double-blind, parallel group, multicentre, stratified, study evaluating the efficacy and safety of once daily fluticasone
furoate (FF)/vilanterol (VI) inhalation powder compared to once daily fluticasone furoate inhalation powder in the treatment of asthma in participants aged 5 to 17 years old (inclusive) currently uncontrolled on inhaled corticosteroids. The package leaflet and labelling are updated accordingly. The RMP version 12.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC; 2) Submission of final report from Phase 2b study HZA106855 (FF dose ranging) which gives information regarding the dose selection for FF combination in study HZA107116; 3) Submission of final report from Phase 2b study HZA106853 (VI dose ranging) which gives information regarding the dose selection for VI combination in study HZA107116

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.13. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/II/0113

**Applicant:** Janssen Biologics B.V.

**PRAC Rapporteur:** Mari Thorn

**Scope:** Submission of the final report from study CNTO148UCO1001 (PURSUIT PEDS PK) listed as a category 3 study in the RMP. This is a phase 1b open-label study to assess the safety and pharmacokinetics of subcutaneously administered golimumab, a human anti-TNFα antibody, in paediatric subjects with moderately to severely active ulcerative colitis. The RMP version 24.1 has also been submitted.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.14. Influenza vaccine (surface antigen, inactivated, adjuvanted) - FLUAD TETRA (CAP) - EMEA/H/C/004993/II/0043

**Applicant:** Seqirus Netherlands B.V.

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** Extension of indication to include adults 50 years of age and older for Fluad Tetra, based on final results from study V118_23; this is a phase 3, randomised, observer-blind, controlled, multicenter, clinical study to evaluate immunogenicity and safety of an MF59-adjuvanted quadrivalent subunit inactivated influenza vaccine in comparison with a licensed quadrivalent influenza vaccine, in adults 50 to 64 years of age. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Labelling and package leaflet are updated in accordance. Version 2.9 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the product information.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.15. Ivacaftor - KALYDECO (CAP) - EMEA/H/C/002494/X/0114/G

**Applicant:** Vertex Pharmaceuticals (Ireland) Limited

**PRAC Rapporteur:** Monica Martinez Redondo

**Scope:** Grouped applications consist of: 1) Extension application to add a new strength (59.5 mg) of the granules pharmaceutical form grouped with a type II variation to support a new indication in a combination regimen with ivacaftor/tezacaftor/elecaftor for the
treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see section 5.1). The RMP (version 15.1) has also been submitted; 2) Type IB B.II.f.1.b - to extend the shelf-life of the granules pharmaceutical form of the finished product as packaged for sale from 3 to 4 years. The product information has been updated accordingly.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.16. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - EMEA/H/C/005269/X/0033, Orphan

**Applicant:** Vertex Pharmaceuticals (Ireland) Limited  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Extension application to add a new pharmaceutical form (granules) associated with 2 new strengths (60 mg/40 mg/80 mg and 75 mg/50 mg/100 mg) to support a new indication in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see section 5.1). The new indication is only applicable to the new granules pharmaceutical form. As a consequence of the line extension the product information for the film coated tablets is also updated to reflect the addition of a new pharmaceutical form. The RMP (version 6.2) has also been submitted.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.17. Lanadelumab - TAKHZYRO (CAP) - EMEA/H/C/004806/X/0034/G, Orphan

**Applicant:** Takeda Pharmaceuticals International AG Ireland Branch  
**PRAC Rapporteur:** Kirsti Villikka  
**Scope:** Grouped application consisting of: 1) Extension application to add a new strength of 150 mg for lanadelumab solution for injection in pre-filled syringe and to extend the indication to include paediatric use (2 to <12 years). The new indication is only applicable to the new 150 mg strength presentations. The RMP (version 3.0) is updated in accordance; 2) a type IB variation (C.I.z) to update section 7 of the package leaflet (PL) for the 300 mg in 2 ml pre-filled syringe (EU/1/18/1340/004-006) in line with the proposed package leaflet for the 150 mg in 1 ml pre-filled syringe (new strength). In addition, the MAH has requested an extension of the Orphan Market Exclusivity from 10 to 12 years.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.18. Maralixibat - LIVMARLI (CAP) - EMEA/H/C/005857/II/0003/G, Orphan

**Applicant:** Mirum Pharmaceuticals International B.V.  
**PRAC Rapporteur:** Adam Przybylkowski  
**Scope:** Grouped variation consisting of: 1) Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 2 months of age and older for LIVMARLI, based on results from studies MRX-502, LUM001-501, MRX-503, MRX-800
and MRX-801; MRX-502 is an international, multicenter, randomised, double-blind, placebo-controlled, parallel group Phase 3 study that evaluated the efficacy and safety of maralixibat in PFIC participants aged >12 months to <18 years on a proposed dosage of up to 600 μg/kg BID over 6 months. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and Annex II are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes; 2) other quality variations

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.19. Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/II/0136

**Applicant:** Biogen Netherlands B.V.  
**PRAC Rapporteur:** Gabriele Maurer  
**Scope:** Update of sections 4.2 and 4.4 of the SmPC to modify administration instructions and update educational guidance to enable the subcutaneous formulation to be administered outside a clinical setting by healthcare professionals based on the cumulative review of post marketing and clinical study data. The package leaflet and Annex IID are updated accordingly. The RMP version 29.1 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.20. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/II/0043/G

**Applicant:** Pfizer Europe MA EEIG  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Grouped variations consisting of: 1) update of section 5.1 of the SmPC in order to include new virology updates; 2) update of sections 4.5 and 5.2 of the SmPC in order to update interaction information related to CYP2B6, MATE1 and OCT1. The RMP version 3.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.21. Nirsevimab - BEYFORTUS (CAP) - EMEA/H/C/005304/II/0005

**Applicant:** AstraZeneca AB  
**PRAC Rapporteur:** Kimmo Jaakkola  
**Scope:** Extension of indication to include treatment of children up to 24 months of age who remain vulnerable to severe Respiratory Syncytial Virus (RSV) disease through their second RSV season for BEYFORTUS, based on interim results from studies D5290C00005 and D5290C00008. Study D5290C00005 (MEDLEY) is a Phase II/III, randomised, double-blind, placebo-controlled study to evaluate the safety of Beyfortus in high-risk children. Study D5290C00008 (MUSIC) is a Phase II, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetics, and occurrence of antidrug antibody for Beyfortus in immunocompromised children ≤ 24 Months of Age. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC are updated. The package leaflet is
updated accordingly. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.22. Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/II/0130

**Applicant:** Bristol-Myers Squibb Pharma EEIG  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Extension of indication to include OPDIVO for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, based on results from study CA20976K; This is a phase III, randomised, double-blind study of adjuvant immunotherapy with nivolumab versus placebo after complete resection of stage IIB/C melanoma. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 33.0 of the RMP has also been submitted.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.23. Obinutuzumab - GAZYVARO (CAP) - EMEA/H/C/002799/II/0052, Orphan

**Applicant:** Roche Registration GmbH  
**PRAC Rapporteur:** Ulla Wändel Liminga  
**Scope:** Extension of indication to include the pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab for Gazyvaro, based on results from study NP30179; this is a multicenter, open-label, Phase I/II study evaluating the safety, efficacy, tolerability and pharmacokinetics of escalating doses of glofitamab as a single agent in combination with obinutuzumab administered after a fixed, single dose pre-treatment of Gazyvaro in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). As a consequence, sections 4.1, 4.2, 4.4, 5.1, 5.3 and 6.6 of the SmPC are updated. The package leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the package leaflet. Furthermore, the product information is brought in line with the latest QRD template version.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.24. Olaparib - LYNPARZA (CAP) - EMEA/H/C/003726/II/0061

**Applicant:** AstraZeneca AB  
**PRAC Rapporteur:** Amelia Cupelli  
**Scope:** Update of sections 4.8 and 5.1 of the SmPC in order to update the overall survival and safety information following procedure H/C/003726/II/0048, based on the final results from study D081SC00001 (PROpel), listed as a PAES in the Annex II; this is a randomised, double-blind, placebo-controlled, multicentre phase III study of olaparib plus abiraterone relative to placebo plus abiraterone as first-line therapy in men with metastatic castration resistant prostate cancer; The RMP version 27 has also been submitted.
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.25. Onasemnogene abeparvovec - ZOLGENSMA (CAP) - EMEA/H/C/004750/II/0040, Orphan

Applicant: Novartis Europharm Limited, ATMP

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of sections 4.4 and 5.1 of the SmPC in order to add a new warning and precaution capturing the theoretical risk of tumorigenicity as a result of vector integration and to include a new statement indicating random instances of vector integration are possible; based on final results from studies 2220205 and 2220117, and literature. The package leaflet is updated accordingly. The RMP version 3 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

### 5.3.26. Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) - FOCLIVIA (CAP) - EMEA/H/C/001208/II/0081

Applicant: Seqirus S.r.l

PRAC Rapporteur: Amelia Cupelli

Scope: Extension of indication to include children from 6 months to less than 18 years of age for Foclivia, based on final results from study V87_30; this is a phase 2, randomised, observer-blind, multicentre study to evaluate the immunogenicity and safety of several doses of antigen and MF59 adjuvant content in a monovalent H5N1 pandemic influenza vaccine in healthy pediatric subjects 6 months to less than 9 years of age. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated accordingly. Version 4.9 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information and to bring it in line with the latest QRD template

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.27. Pegcetacoplan - ASPAVELI (CAP) - EMEA/H/C/005553/II/0011, Orphan

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor for ASPAVELI, based on final results from study APL2-308. This is a Phase III, randomised, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.28. Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0133

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma for Keytruda, based on interim results from study KEYNOTE-811, an ongoing Phase 3, double-blind trial comparing trastuzumab plus chemotherapy and pembrolizumab with trastuzumab plus chemotherapy and placebo as first-line treatment in participants with HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma. As a consequence, sections 4.1, 4.8, and 5.1 of the SmPC are updated. The package leaflet and Labelling are updated in accordance. Version 40.1 of the RMP has also been submitted.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - APEXXNAR (CAP) - EMEA/H/C/005451/II/0012

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Jean-Michel Dogné

Scope: Extension of indication to include infants, children and adolescents from 6 weeks to less than 18 years of age for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae, based on final results from studies B7471003, B7471011, B7471012, B7471013 and B7471014. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - APEXXNAR (CAP) - EMEA/H/C/005451/II/0016

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Jean-Michel Dogné

Scope: Submission of an updated RMP version 4 in order to update post-approval commitments. In addition, the MAH took the opportunity to update Annex II of the SmPC to expand the B4741015 PAES study protocol to sites in Europe and Israel for Apexxnar. B4741015 is a Phase 4 study using a test negative design to evaluate the effectiveness of Apexxnar against vaccine type radiologically confirmed community acquired pneumonia in adults ≥ 65 years of age.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.31. Risdiplam - EVRYSDI (CAP) - EMEA/H/C/005145/II/0005/G, Orphan

Applicant: Roche Registration GmbH

PRAC Rapporteur: Jan Neuhauser
Scope: Grouped variations consisting of: 1) extension of indication to include treatment of patients below 2 months of age based on interim results from pivotal study BN40703 (RAINBOWFISH): an ongoing phase 2 multicentre, open-label, and single-arm study designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) of risdiplam in pre-symptomatic infants below 2 months of age who were genetically diagnosed with spinal muscular atrophy (SMA). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, the MAH took the opportunity to make some editorial improvements in the product information; 2) update of Evrysdi (risdiplam) pack configuration As a consequence, section 6.5 of the SmPC and the labelling are updated; 3) removal of a device. As a consequence, section 6.5 of the SmPC and the labelling are updated. The package leaflet and the RMP (version 1.1) are updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.32. Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0021

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Menno van der Elst

Scope: Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET) fusion-positive thyroid cancer in the first-line setting for RETSEVMO based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumors. LIBRETTO-121 is a Phase 1/2 study of selpercatinib in paediatric patients with advanced RET-altered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.33. Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0022

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Menno van der Elst

Scope: Extension of indication to include the treatment of adults with advanced or metastatic rearranged during transfection (RET) fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no satisfactory therapeutic options, based on interim data from study LIBRETTO-001 (LOXO-RET-17001); LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.34. Siponimod - MAYZENT (CAP) - EMEA/H/C/004712/II/0020

**Applicant:** Novartis Europharm Limited  
**PRAC Rapporteur:** Maria del Pilar Rayon  
**Scope:** Update of sections 4.4 and 4.8 of the SmPC in order to add “Progressive multifocal leukoencephalopathy (PML)” to the list of adverse drug reactions (ADRs) with frequency “not known” based on post-marketing data. The Annex II (Physician’s Checklist), and package leaflet are updated accordingly. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the text regarding herpes viral infection in the package leaflet in alignment with the currently approved SmPC  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.35. Sotorasib - LUMYKRAS (CAP) - EMEA/H/C/005522/II/0007

**Applicant:** Amgen Europe B.V.  
**PRAC Rapporteur:** Marie Louise Schougaard Christiansen  
**Scope:** Update of sections 4.2 and 5.2 of the SmPC in order to update recommendations for patients with moderate to severe hepatic impairment following final results from study 20200362 listed as a category 3 PASS study in the EU RMP; this is a Phase I clinical study to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in subjects with moderate or severe hepatic impairment compared with subjects who have normal hepatic function. The EU RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.36. Teclistamab - TECVAYLI (CAP) - EMEA/H/C/005865/II/0006

**Applicant:** Janssen-Cilag International N.V.  
**PRAC Rapporteur:** Jana Lukacisinova  
**Scope:** Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update the posology recommendations to include the possibility of bi-weekly dosing, based on interim results from study 64007957MMY1001 (MajesTEC-1); this is a phase 1/2, single-arm, open-label, multicenter study of teclistamab administered as monotherapy to adult subjects with relapsed or refractory multiple myeloma. The package leaflet is updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3 and update the list of local representatives in the package leaflet  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.37. Teriflunomide - TERIFLUNOMIDE ACCORD (CAP) - EMEA/H/C/005960/X/0002

**Applicant:** Accord Healthcare S.L.U.  
**PRAC Rapporteur:** Martin Huber
Scope: Extension application to add a new strength of 7 mg film-coated tablets. The bioequivalence study data were submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.38. Tixagevimab, cilgavimab - EVUSHELD (CAP) - EMEA/H/C/005788/II/0009/G

**Applicant:** AstraZeneca AB  
**PRAC Rapporteur:** Kimmo Jaakkola  
**Scope:** Grouped application consisting of: 1) Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study TACKLE (D8851C00001); 2) Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on final results from studies PROVENT (D8850C00002) and STORM CHASER (D8850C00003). The RMP version 4.1 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.39. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/II/0027

**Applicant:** Daiichi Sankyo Europe GmbH  
**PRAC Rapporteur:** Inês Ribeiro-Vaz  
**Scope:** Extension of indication to include the indication treatment of non-small cell lung cancer for Enhertu (trastuzumab deruxtecan), based on results from study DS8201-A-U204 (DESTINY-Lung01) and study DS8201-A-U206 (DESTINY-Lung02). Study DESTINY-Lung01 is a phase 2, multicentre, open-label, 2-cohort study of trastuzumab deruxtecan (DS-8201a), an anti-HER2 antibody drug conjugate (ADC), for HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer (NSCLC) conducted at sites in Japan, the United States and Europe. Study DESTINY-Lung02 is an ongoing phase 2, multicentre, randomised study to evaluate the safety and efficacy of trastuzumab deruxtecan in subjects with HER2-mutated metastatic non-small cell lung cancer, conducted in North America, Europe and Asia-Pacific. As a consequence, sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 2.2 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.40. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/II/0031

**Applicant:** Daiichi Sankyo Europe GmbH  
**PRAC Rapporteur:** Inês Ribeiro-Vaz  
**Scope:** Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update safety, efficacy and pharmacokinetic information based on data from study DS8201-A-U301 and study DS8201-A-U302. Study U301 was a Phase 3, randomised, 2-arm, open-label, multicenter study designed to compare the safety and efficacy of T-DXd vs TPC in HER2-positive, unresectable and/or metastatic BC subjects who were resistant or refractory to T-DM1. Study U302 was a Phase 3, multicenter, randomised, open-label, 2-arm, active-controlled study in subjects with unresectable and/or metastatic HER2-positive (IHC 3+ or ISH-
positive) BC previously treated with trastuzumab plus taxane in the advanced/metastatic setting or who had progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab plus taxane. The package leaflet and Annex II are updated accordingly. The updated RMP version 4.1 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 6. Periodic safety update reports (PSURs)

#### 6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

**6.1.1. Aflibercept** - EYLEA (CAP) - PSUSA/00010020/202211

- **Applicant:** Bayer AG
- **PRAC Rapporteur:** Nathalie Gault
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

**6.1.2. Angiotensin II** - GIAPREZA (CAP) - PSUSA/00010785/202212

- **Applicant:** Paion Deutschland GmbH
- **PRAC Rapporteur:** Menno van der Elst
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

**6.1.3. Artesunate** - ARTESUNATE AMIVAS (CAP) - PSUSA/00010958/202212

- **Applicant:** Amivas Ireland Ltd
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

**6.1.4. Atidarsagene autotemcel** - LIBMELDY (CAP) - PSUSA/00010899/202212

- **Applicant:** Orchard Therapeutics (Netherlands) B.V., ATMP
- **PRAC Rapporteur:** Gabriele Maurer
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CAT and CHMP

---

5 Ophthalmological indication(s) only
6 Advanced therapy medicinal product
6.1.5. Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - STRIVMELIS (CAP) - PSUSA/00010505/202211

Applicant: Orchard Therapeutics (Netherlands) B.V., ATMP
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CAT and CHMP

6.1.6. Berotralstat - ORLADEYO (CAP) - PSUSA/00010930/202212

Applicant: BioCryst Ireland Limited
PRAC Rapporteur: Julia Pallos
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.7. Blinatumomab - BLINCYTO (CAP) - PSUSA/00010460/202212

Applicant: Amgen Europe B.V.
PRAC Rapporteur: Jana Lukacisinova
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.8. Budesonide - KINPEYGO (CAP) - PSUSA/00011007/202212

Applicant: STADA Arzneimittel AG
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.9. Buprenorphine - SIXMO (CAP) - PSUSA/00010778/202211

Applicant: L. Molteni & C. dei Fratelli Alitti Societa di Esercizio S.p.A.
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

---

7 Advanced therapy medicinal product
8 For centrally authorised products indicated for primary immunoglobulin A nephropathy only
9 Implant(s) only
6.1.10. **Coronavirus (COVID-19) vaccine (recombinant, adjuvanted) - NUVAXOVID (CAP) - PSUSA/00010972/202212**

Applicant: Novavax CZ, a.s.
PRAC Rapporteur: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.11. **Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - PSUSA/00010912/202212**

Applicant: AstraZeneca AB
PRAC Rapporteur: Jean-Michel Dogné
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.12. **Dengue tetravalent vaccine (live, attenuated) - DENGVAXIA (CAP) - PSUSA/00010740/202212**

Applicant: Sanofi Pasteur
PRAC Rapporteur: Sonja Hrabcik
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.13. **Efgartigimod alfa - VYVGART (CAP) - PSUSA/00011014/202212**

Applicant: Argenx
PRAC Rapporteur: Rhea Fitzgerald
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP


Applicant: PTC Therapeutics International Limited, ATMP\(^\text{10}\)
PRAC Rapporteur: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CAT and CHMP

\(^{10}\) Advanced therapy medicinal product
6.1.15. Elasomeran (Spikevax), elasomeran, imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran, davesomeran (Spikevax bivalent Original/Omicron BA.4-5) - SPIKEVAX (CAP) - PSUSA/00010897/202212 (with RMP)

Applicant: Moderna Biotech Spain, S.L.
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.16. Enfortumab vedotin - PADCEV (CAP) - PSUSA/00010989/202212

Applicant: Astellas Pharma Europe B.V.
PRAC Rapporteur: Eva Jirsová
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.17. Entrectinib - ROZLYTREK (CAP) - PSUSA/00010874/202212

Applicant: Roche Registration GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.18. Fenfluramine - FINTEPLA (CAP) - PSUSA/00010907/202212

Applicant: UCB Pharma SA
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.19. Formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - RILTRAVA AEROSPHERE (CAP); TRIXEO AEROSPHERE (CAP) - PSUSA/00010908/202212

Applicant: AstraZeneca AB
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.20. Human papillomavirus vaccine (rDNA) - 2-valent - CERVARIX (CAP) - PSUSA/00009175/202211

Applicant: GlaxoSmithkline Biologicals SA
6.1.21. **Hydroxocobalamin**\(^{11}\) - **CYANOKIT (CAP)** - **PSUSA/00010228/202211**

**Applicant:** SERB SA  
**PRAC Rapporteur:** Nathalie Gault  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

---

6.1.22. **Indacaterol** - **HIROBRIZ BREEZHALER (CAP); ONBREZ BREEZHALER (CAP); OSLIF BREEZHALER (CAP)** - **PSUSA/00001730/202211**

**Applicant:** Novartis Europharm Limited  
**PRAC Rapporteur:** Marie Louise Schougaard Christiansen  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

---

6.1.23. **Inebilizumab** - **UPLIZNA (CAP)** - **PSUSA/00010996/202212**

**Applicant:** Horizon Therapeutics Ireland DAC  
**PRAC Rapporteur:** Amelia Cupelli  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

---

6.1.24. **Inotuzumab ozogamicin** - **BESPONSA (CAP)** - **PSUSA/00010659/202212**

**Applicant:** Pfizer Europe MA EEIG  
**PRAC Rapporteur:** Gabriele Maurer  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

---

6.1.25. **Larotrectinib** - **VITRAKVI (CAP)** - **PSUSA/00010799/202211**

**Applicant:** Bayer AG  
**PRAC Rapporteur:** Rugile Pilviniene  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

\(^{11}\) Only for product(s) for chemical poisoning
6.1.26.  Latanoprost, netarsudil - ROCLANDA (CAP) - PSUSA/00010905/202212

Applicant: Santen Oy
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.27.  Levodopa - INBRIJA (CAP) - PSUSA/00107800/202212

Applicant: Acorda Therapeutics Ireland Limited
PRAC Rapporteur: Nikica Mirošević Skvrce
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.28.  Luspatercept - REBLOZYL (CAP) - PSUSA/00010860/202212

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Jo Robays
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.29.  Lutetium (\textsuperscript{177}Lu) oxodotreotide - LUTATHERA (CAP) - PSUSA/00010643/202212

Applicant: Advanced Accelerator Applications
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.30.  Lutropin alfa - LUVERIS (CAP) - PSUSA/00001918/202211

Applicant: Merck Europe B.V.
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.31.  Mexiletine\textsuperscript{12} - NAMUSCLA (CAP) - PSUSA/00010738/202212

Applicant: Lupin Europe GmbH
PRAC Rapporteur: Eva Jirsová

\textsuperscript{12} Centrally authorised product(s) only
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.32. Mosunetuzumab - LUNSUMIO (CAP) - PSUSA/00010999/202212

Applicant: Roche Registration GmbH
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.33. Obeticholic acid - OCALIVA (CAP) - PSUSA/00010555/202211

Applicant: Advanz Pharma Limited
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.34. Olaparib - LYNPARZA (CAP) - PSUSA/00010322/202212

Applicant: AstraZeneca AB
PRAC Rapporteur: Amelia Cupelli
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.35. Pegvisomant - SOMAVER (CAP) - PSUSA/00002328/202211

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Nathalie Gault
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.36. Pertuzumab, trastuzumab - PHESGO (CAP) - PSUSA/00010906/202212

Applicant: Roche Registration GmbH
PRAC Rapporteur: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP
6.1.37. **Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - APEXXNAR (CAP) - PSUSA/00010981/202212**

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Jean-Michel Dogné
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.38. **Relugolix, estradiol, norethisterone acetate - RYEQO (CAP) - PSUSA/00010942/202211**

Applicant: Gedeon Richter Plc.
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.39. **Roxadustat - EVRENZO (CAP) - PSUSA/00010955/202212**

Applicant: Astellas Pharma Europe B.V.
PRAC Rapporteur: Anna Mareková
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.40. **Rucaparib - RUBRACA (CAP) - PSUSA/00010694/202212**

Applicant: Zr Pharma& GmbH
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.41. **Satralizumab - ENSPRYNG (CAP) - PSUSA/00010944/202211**

Applicant: Roche Registration GmbH
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.42. **Sotorasib - LUMYKRAS (CAP) - PSUSA/00010970/202211**

Applicant: Amgen Europe B.V.
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.43. Tagraxofusp - ELZONRIS (CAP) - PSUSA/00010896/202212

Applicant: Stemline Therapeutics B.V.
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.44. Tezepelumab - TEZSPIRE (CAP) - PSUSA/00011015/202212

Applicant: AstraZeneca AB
PRAC Rapporteur: Eva Jirsová
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.45. Tirbanibulin - KLISYRI (CAP) - PSUSA/00010943/202212

Applicant: Almirall, S.A.
PRAC Rapporteur: Anna Mareková
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.46. Tozinameran (COMIRNATY), tozinameran, riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran, famtozinameran (COMIRNATY Original/Omicron BA.4-5) - COMIRNATY (CAP) - PSUSA/00010898/202212

Applicant: BioNTech Manufacturing GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.47. Tralokinumab - ADTRALZA (CAP) - PSUSA/00010937/202212

Applicant: LEO Pharma A/S
PRAC Rapporteur: Kimmo Jaakkola
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP
6.1.48. Trastuzumab deruxtecan - ENHERTU (CAP) - PSUSA/00010894/202212

Applicant: Daiichi Sankyo Europe GmbH
PRAC Rapporteur: Inês Ribeiro-Vaz
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.49. Turoctocog alfa pegol - ESPEROCT (CAP) - PSUSA/00010782/202212

Applicant: Novo Nordisk A/S
PRAC Rapporteur: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.50. Vutrisiran - AMVUTTRA (CAP) - PSUSA/00011021/202212

Applicant: Alnylam Netherlands B.V.
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

6.2.1. Acetylsalicylic acid, clopidogrel, clopidogrel - CLOPIDOGREL ZENTIVA (CAP); DUOPLAVIN (CAP); ISCOVER (CAP); PLAVIX (CAP); NAP - PSUSA/00000820/202211

Applicant(s): Zentiva k.s. (Clopidogrel Zentiva), Sanofi Winthrop Industrie (DuoPlavix, Iscover, Plavix), various
PRAC Rapporteur: Inês Ribeiro-Vaz
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.2.2. Docetaxel - TAXOTERE (CAP); NAP - PSUSA/00001152/202211

Applicant(s): Sanofi Mature IP (Taxotere), various
PRAC Rapporteur: Tiphaine Vaillant
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP
6.2.3. **Edotreotide - SOMAKIT TOC (CAP); NAP - PSUSA/00010552/202212**

- **Applicant(s):** Advanced Accelerator Applications (SomaKit TOC), various
- **PRAC Rapporteur:** Eamon O'Murchu
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

6.3.1. **Alfuzosin (NAP) - PSUSA/00000084/202211**

- **Applicant(s):** various
- **PRAC Lead:** Ulla Wändel Liminga
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

6.3.2. **Amlodipine (NAP), indapamide, amlodipine (NAP), indapamide (NAP), perindopril (NAP) - PSUSA/00010358/202211**

- **Applicant(s):** various
- **PRAC Lead:** Menno van der Elst
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

6.3.3. **Apomorphine (NAP) - PSUSA/00000227/202211**

- **Applicant(s):** various
- **PRAC Lead:** Marie Louise Schougaard Christiansen
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

6.3.4. **Bacillus clausii multi-antibioresistant spores (NAP) - PSUSA/00000284/202211**

- **Applicant(s):** various
- **PRAC Lead:** Amelia Cupelli
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh
6.3.5. **Bambuterol (NAP) - PSUSA/00000295/202212**

Applicant(s): various  
PRAC Lead: Jana Lukačišinová  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.6. **Bromperidol (NAP) - PSUSA/00000439/202211**

Applicant(s): various  
PRAC Lead: Liana Gross-Martirosyan  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.7. **Brotizolam (NAP) - PSUSA/00000444/202212**

Applicant(s): various  
PRAC Lead: Ana Sofia Diniz Martins  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.8. **Caffeine, ergotamine (NAP) - PSUSA/00000485/202211**

Applicant(s): various  
PRAC Lead: Tiphaine Vaillant  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.9. **Cetirizine (NAP) - PSUSA/00000628/202211**

Applicant(s): various  
PRAC Lead: Kirsti Villikka  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.10. **Dienogest (NAP) - PSUSA/00003167/202212**

Applicant(s): various  
PRAC Lead: Menno van der Elst  
Scope: Evaluation of a PSUSA procedure
6.3.11. **Dutasteride (NAP), dutasteride, tamsulosine (NAP) - PSUSA/00010506/202211**

**Action:** For adoption of recommendation to CMDh

Applicant(s): various
PRAC Lead: Melinda Palfi
Scope: Evaluation of a PSUSA procedure

6.3.12. **Econazole (NAP), econazole nitrate, triamcinolone acetonide (NAP), econazole nitrate, zinc oxide (NAP) - PSUSA/00001195/202211**

Applicant(s): various
PRAC Lead: Melinda Palfi
Scope: Evaluation of a PSUSA procedure

6.3.13. **Flurbiprofen (NAP) - PSUSA/00001450/202211**

Applicant(s): various
PRAC Lead: Valentina Di Giovanni
Scope: Evaluation of a PSUSA procedure

6.3.14. **Horse-derived anti-T lymphocyte immunoglobulin for human use (NAP) - PSUSA/00010433/202211**

Applicant(s): various
PRAC Lead: Zane Neikena
Scope: Evaluation of a PSUSA procedure

6.3.15. **Hydroxyurea**¹³ (NAP) - PSUSA/00009182/202212

Applicant(s): various
PRAC Lead: Nikica Mirošević Skvrce
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

¹³ Except for centrally authorised product
6.3.16. **Idarubicin (NAP) - PSUSA/00001720/202211**

Applicant(s): various  
PRAC Lead: Jan Neuhauser  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.17. **Inactivated leptospire vaccine (NAP) - PSUSA/00010813/202211**

Applicant(s): various  
PRAC Lead: Nathalie Gault  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.18. **Lamotrigine (NAP) - PSUSA/00001825/202211**

Applicant(s): various  
PRAC Lead: Liana Gross-Martirosyan  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.19. **Levocabastine (NAP) - PSUSA/00001849/202211**

Applicant(s): various  
PRAC Lead: Marie Louise Schougaard Christiansen  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.20. **Mizolastine (NAP) - PSUSA/00002078/202211**

Applicant(s): various  
PRAC Lead: Jana Lukačišinová  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.21. **Naltrexone (NAP) - PSUSA/00002117/202211**

Applicant(s): various  
PRAC Lead: Eamon O’Murchu  
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

### 6.3.22. Propofol (NAP) - PSUSA/00002555/202211

- **Applicant(s):** various
- **PRAC Lead:** Karen Pernille Harg
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.23. Rosuvastatin (NAP) - PSUSA/00002664/202211

- **Applicant(s):** various
- **PRAC Lead:** Menno van der Elst
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.24. Sodium fluoride (18F) (NAP) - PSUSA/00010706/202211

- **Applicant(s):** various
- **PRAC Lead:** Kimmo Jaakkola
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.25. Yellow fever vaccine (live) (NAP) - PSUSA/00003135/202212

- **Applicant(s):** various
- **PRAC Lead:** Gabriele Maurer
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.4. Follow-up to PSUR/PSUSA procedures

#### 6.4.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/LEG 115

- **Applicant:** AstraZeneca AB
- **PRAC Rapporteur:** Jean-Michel Dogné
- **Scope:** Submission of a cumulative review of cases of myocarditis, including a causality assessment according to WHO-UMC criteria for cases with Brighton Collaboration Classification (BCC) case definition level 1, 2 or 3, a discussion on the O/E analysis for myocarditis based on EU/UK data and on Australian data, with stratifications by risk window
(7, 14, 21, 42 days), age group, gender and dose, together with a literature review, as per conclusions of the PSUSA/00010916/202208 adopted in April 2023

**Action:** For adoption of advice to CHMP

### 6.4.2. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/LEG 017.2

**Applicant:** Pfizer Europe MA EEIG

**PRAC Rapporteur:** Martin Huber

**Scope:** Submission of a justification for not submitting a variation regarding an update of the Paxlovid product information to add myalgia as an adverse drug reaction

**Action:** For adoption of advice to CHMP

### 6.5. Variation procedure(s) resulting from PSUSA evaluation

#### 6.5.1. Fondaparinux sodium - ARIXTRA (CAP) - EMEA/H/C/000403/II/0087

**Applicant:** Mylan Ire Healthcare Limited

**PRAC Rapporteur:** Mari Thorn

**Scope:** To update section 4.8 of the SmPC to update the ADR table following the assessment of PSUSA (EMEA/H/C/PSUSA/00001467/202112). The package leaflet is updated accordingly

**Action:** For adoption of PRAC Assessment Report

### 6.6. Expedited summary safety reviews

None

### 7. Post-authorisation safety studies (PASS)

#### 7.1. Protocols of PASS imposed in the marketing authorisation(s)

#### 7.1.1. Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/PSA/S/0102.2

**Applicant:** Kite Pharma EU B.V., ATMP

**PRAC Rapporteur:** Marie Louise Schougaard Christiansen

**Scope:** Substantial amendment to a protocol for a long-term, non-interventional study of recipients of Yescarta for treatment of relapsed or refractory Diffuse Large B-cell Lymphoma

---

14 Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

15 In accordance with Article 107n of Directive 2001/83/EC

16 Advanced therapy medicinal product
and Primary Mediastinal B-cell Lymphoma [MAH’s further response to PSA/S/0102]

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.1.2. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/PSA/S/0093.2

**Applicant:** Bristol-Myers Squibb Pharma EEIG

**PRAC Rapporteur:** Tiphaine Vaillant

**Scope:** Substantial amendment to a protocol for a post-authorisation, non-interventional, retrospective, drug-utilisation study to describe the pattern of use of lenalidomide in patients with myelodysplastic syndromes (MDS) [MAH’s response to PSA/S/0093.1]

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.1.3. Valproate\(^\text{17}\) (NAP) – EMEA/H/N/PSP/J/0074.7

**Applicant:** Sanofi-Aventis Recherche & Développement

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** Responses to the RSI of the 2\(^\text{nd}\) Interim report: Observational study to evaluate and identify the best practices for switching of valproate in clinical practice

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)\(^\text{18}\)

#### 7.2.1. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/MEA 015

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Adam Przybylkowski

**Scope:** Submission of a protocol for study I4V-MC-B025: Rheumatologist and Dermatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant (baricitinib), a JAK1/2 Inhibitor

**Action:** For adoption of advice to CHMP

#### 7.2.2. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/MEA 016

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Adam Przybylkowski

**Scope:** Submission of a protocol for study I4V-MC-B038: Baricitinib Drug Utilisation Study: Assessment of Effectiveness of New Recommendations for Use Based on Secondary Data Sources in France, Germany, The Netherlands, and Sweden. This study aims to assess the utilisation of baricitinib in patients with RA, AA, or AD with respect to the new

\(^{17}\) Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnesium

\(^{18}\) In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
recommendations further to the completion of the Pharmacovigilance article 20 in the aRMMs (DHPC, Healthcare Professional educational materials, and Patient Alert Card)

**Action:** For adoption of advice to CHMP

### 7.2.3. Coronavirus (COVID-19) vaccine (recombinant, adjuvanted) - NUVAXOVID (CAP) - EMEA/H/C/005808/MEA 004.3

**Applicant:** Novavax CZ, a.s.

**PRAC Rapporteur:** Gabriele Maurer

**Scope:** Submission of an updated protocol (version 3.0) and statistical analysis plan (v. 1.0) for study 2019nCoV-402

**Action:** For adoption of advice to CHMP

### 7.2.4. Daridorexant - QUVIVIQ (CAP) - EMEA/H/C/005634/MEA 003

**Applicant:** Idorsia Pharmaceuticals Deutschland GmbH

**PRAC Rapporteur:** Ana Sofia Diniz Martins

**Scope:** Submission of a pregnancy registry protocol ID-078A403 to compare the maternal, foetal, and infant outcomes of women exposed to daridorexant during pregnancy to an unexposed control population

**Action:** For adoption of advice to CHMP

### 7.2.5. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/MEA 002.1

**Applicant:** Argenx

**PRAC Rapporteur:** Rhea Fitzgerald

**Scope:** MAH’s response to MEA 002 [Submission of a protocol for a PASS to characterise the risks and missing information outlined in the risk management plan including serious infections, use of live/attenuated vaccines, use with monoclonal antibodies, long-term safety and use in immunocompromised patients and evaluate whether there are specific and/or unexpected patterns of adverse events] as per the request for supplementary information (RSI) adopted in February 2023

**Action:** For adoption of advice to CHMP

### 7.2.6. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/MEA 004.1

**Applicant:** Argenx

**PRAC Rapporteur:** Rhea Fitzgerald

**Scope:** MAH’s response to MEA 004 [Submission of a protocol for a PASS to characterise the missing information use in pregnant woman outlined in the risk management plan] as per the request for supplementary information (RSI) adopted in February 2023

**Action:** For adoption of advice to CHMP
7.2.7. Fremanezumab - AJOVY (CAP) - EMEA/H/C/004833/MEA 003.3

Applicant: TEVA GmbH
PRAC Rapporteur: Kirsti Villikka
Scope: Submission of a protocol amendment 4.0 for study TV48125-MH-50038: Assessment of Pregnancy Outcomes in Patients Treated with AJOVY (Fremanezumab): Pregnancy Database Study
Action: For adoption of advice to CHMP

7.2.8. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/MEA 008.1

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Martin Huber
Scope: Submission of a protocol amendment 2 for studyC4671037: use and safety of Paxlovid in pregnant and breastfeeding women
Action: For adoption of advice to CHMP

7.2.9. Nirmatrelvir, ritonavir - PAXLOVID (CAP) - EMEA/H/C/005973/MEA 009.2

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Martin Huber
Scope: MAH's response and Revised Protocol for Study C4671047 (amendment 1) - use and safety of Paxlovid among patients with moderate or severe hepatic or renal impairment as per request for supplementary information (RSI) adopted in February 2023
Action: For adoption of advice to CHMP

7.2.10. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/MEA 005.6

Applicant: BioMarin International Limited
PRAC Rapporteur: Rhea Fitzgerald
Scope: Submission of a revised protocol for study 165-504: a global, multicentre study to assess maternal, foetal and infant outcomes of exposure to Palynziq (pegvaliase) during pregnancy and breastfeeding as per request for supplementary information (RSI) adopted in February 2023
Action: For adoption of advice to CHMP

7.2.11. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.6

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: Submission of a protocol amendment for study OP0005: a European non-interventional PASS to study the adherence to the risk minimisation measures (RMMs) in
the product information by estimating the compliance with contraindications and target indication(s) amongst incident romosozumab users, and analysing the utilisation pattern using the EU-adverse drug reactions (EU-ADR) Alliance

**Action:** For adoption of advice to CHMP

### 7.2.12. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.6

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Submission of a protocol amendment for study OP0004: European non-interventional PASS to evaluate potential differences in terms of serious cardiovascular adverse events between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance

**Action:** For adoption of advice to CHMP

### 7.2.13. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.4

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Submission of a protocol amendment for study OP0006: evaluate potential differences in terms of serious infection between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance

**Action:** For adoption of advice to CHMP

### 7.2.14. Talimogene laherparepvec - IMLYGIC (CAP) - EMEA/H/C/002771/MEA 005.2

Applicant: Amgen Europe B.V., ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: MAH’s response to MEA 005.1 [Submission of a protocol amendment for study 20130193: a post-marketing, prospective cohort study of patients treated with talimogene laherparepvec in clinical practice to characterize the risk of herpetic illness among patients, close contacts, and healthcare providers; and long term safety in treated patients] as per the request for supplementary information (RSI) adopted in March 2023

**Action:** For adoption of advice to CAT and CHMP

### 7.2.15. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 017.3

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of a protocol amendment v4.0 for study A3921352: an active surveillance, post-authorisation study to characterize the safety of tofacitinib in patients

---

19 Advanced therapy medicinal product
with moderately to severely active ulcerative colitis in the real-world setting using data from the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)

**Action:** For adoption of advice to CHMP

### 7.2.16. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 014.3

**Applicant:** AbbVie Deutschland GmbH & Co. KG  
**PRAC Rapporteur:** Nikica Mirošević Skvrce  
**Scope:** MAH’s response to MEA 014.2 [protocol for study P21-824: a study of growth and development in adolescents with atopic dermatitis who receive upadacitinib] as per request for supplementary information (RSI) adopted in January 2023

**Action:** For adoption of advice to CHMP

### 7.3. Results of PASS imposed in the marketing authorisation(s)\(^{20}\)

#### 7.3.1. Trasylol (NAP) - EMEA/H/N/PSR/S/0030

**Applicant:** Nordic Group BV  
**PRAC Rapporteur:** Jean-Michel Dogné  
**Scope:** Submission of the final report from the Nordic Aprotinin Patient Registry to record utilisation information on patients at cardiac surgery centres

**Action:** For adoption of recommendation to CMDh (or request for supplementary information (RSI))

#### 7.3.2. Valproate\(^{21}\) (NAP) - EMEA/H/N/PSR/J/0043

**Applicant:** Sanofi-Aventis Recherche & Développement  
**PRAC Rapporteur:** Liana Gross-Martirosyan  
**Scope:** Final study report for a retrospective observational study to investigate the association between paternal exposure to valproate and the risk of congenital anomalies and neurodevelopmental disorders including autism in offspring

**Action:** For adoption of revised list of questions (LoQ)/timetable

---

\(^{20}\) In accordance with Article 107p-q of Directive 2001/83/EC  
\(^{21}\) Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnesium
7.4. Results of PASS non-imposed in the marketing authorisation(s)\(^{22}\)

7.4.1. Agalsidase alfa - REPLAGAL (CAP) - EMEA/H/C/000369/II/0126

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of the final report from the Fabry Outcome Survey (FOS) registry study. The FOS (Fabry Outcome Survey) was a prospective, multicenter, observational, open-ended disease registry designed to document the clinical outcome over time of patients with Fabry disease, irrespective of their treatment

Action: For adoption of PRAC Assessment Report

7.4.2. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/II/0061, Orphan

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Jo Robays

Scope: Update of sections 4.2 and 4.4 of the SmPC in order to update treatment duration based on final results from EU PASS (protocol no. 242-12-402), listed as a category 3 study in the RMP. This is a “A Multicentre, EU-wide, Non-Interventional Post-Approval Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis (MDR-TB) Patients”. This treatment registry was for monitoring and documenting Deltyba use in routine medical practice and aimed to assess compliance with the recommendations in the authorised product information when prescribed as part of an appropriate combination regimen (ACR) for the treatment of MDR-TB. The package leaflet is updated accordingly. The RMP version 4.2 has also been submitted. In addition, the MAH took the opportunity to update Annex II section D of the SmPC

Action: For adoption of PRAC Assessment Report

7.4.3. Eribulin - HALAVEN (CAP) - EMEA/H/C/002084/II/0067

Applicant: Eisai GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of the final report from study IRENE 504 (E7389-M044-504), listed as a category 3 study in the RMP. This was a post authorisation non-interventional safety study to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and frequency and time to resolution of eribulin-induced PN in adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease treated with eribulin. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. The RMP version 8 has also been submitted

Action: For adoption of PRAC Assessment Report

---

\(^{22}\) In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
7.4.4. Etelcalcetide - PARSABIV (CAP) - EMEA/H/C/003995/II/0021

Applicant: Amgen Europe B.V.
PRAC Rapporteur: Valentina Di Giovanni

Scope: Submission of the final report from study 20170561 listed as a category 3 study in the RMP. This is an observational PASS to evaluate the potential association between Parsabiv and gastrointestinal bleeding

Action: For adoption of PRAC Assessment Report

7.4.5. Gilteritinib - XOSPATA (CAP) - EMEA/H/C/004752/II/0012, Orphan

Applicant: Astellas Pharma Europe B.V.
PRAC Rapporteur: Martin Huber

Scope: Submission of the final report from study 2215-PV-0001 - Evaluation of the effectiveness of the Xospata Routine Risk Minimization Measures (RMMs) and an additional Risk Minimisation Measure (aRMM): A Cross sectional study among Healthcare Professionals to assess awareness and knowledge, listed as a category 3 study in the RMP. The RMP version 3.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.6. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0241

Applicant: Janssen Biologics B.V.
PRAC Rapporteur: Mari Thorn

Scope: Submission of the final report for the PSOLAR (C0168Z03) registry ”A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics: PSOLAR”, listed as a category 3 study in the RMP (MEA114). This is an international, multicenter, prospective observational registry for monitoring the long-term safety experience and clinical status of patients≥18 years of age who are eligible to receive or are actively receiving any systemic therapies for psoriasis, including those currently receiving or planning to receive infliximab. The RMP version 21.1 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.7. Pegfilgrastim - NEULASTA (CAP) - EMEA/H/C/000420/II/0121

Applicant: Amgen Europe B.V.
PRAC Rapporteur: Menno van der Elst

Scope: Submission of the final report from PASS study 20170701 listed as a category 3 study in the RMP. This is a cross-sectional survey study to Assess the Effectiveness of the Neulasta Patient Alert Card and to Measure Medication Errors Related to the Use of the Neulasta On-Body Injector. The RMP version 9.0 has also been submitted

Action: For adoption of PRAC Assessment Report
7.4.8. Tezacaftor, ivacaftor - SYMKEVI (CAP) - EMEA/H/C/004682/II/0039, Orphan

Applicant: Vertex Pharmaceuticals (Ireland) Limited
PRAC Rapporteur: Rhea Fitzgerald
Scope: Submission of the final report from PASS study VX17-661-117 listed as a category 3 study in the RMP. This is an Observational Study to Evaluate the Utilization Patterns and Real-World Effects of Tezacaftor and Ivacaftor Combination Therapy (TEZ/IVA) in Patients With Cystic Fibrosis (CF). The RMP version 3.4 has also been submitted
Action: For adoption of PRAC Assessment Report

7.4.9. Vedolizumab - ENTYVIO (CAP) - EMEA/H/C/002782/II/0073

Applicant: Takeda Pharma A/S
PRAC Rapporteur: Adam Przybylkowski
Scope: Submission of the final report from study MLN0002_401 (listed as a category 3 study in the RMP in order to fulfil MEA/001.2): an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s disease. The RMP version 8.0 has also been submitted
Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Ataluren - TRANSLARNA (CAP) - EMEA/H/C/002720/MEA 002.9

Applicant: PTC Therapeutics International Limited
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Post-approval registry Protocol PTC124-GD-0250-DMD: Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Action: For adoption of advice to CHMP

7.5.2. Cabazitaxel - CABAZITAXEL ACCORD (CAP) - EMEA/H/C/005178/MEA 001.4

Applicant: Accord Healthcare S.L.U.
PRAC Rapporteur: Tiphaine Vaillant
Scope: The fifth six-monthly safety report for the category 3 study to review the cases reported for ‘medication error’
Action: For adoption of advice to CHMP

7.5.3. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 004.9

Applicant: Moderna Biotech Spain, S.L.
PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Fourth interim report for study mRNA-1273-P904 (study 1) (listed as a category 3 study in the RMP): a post-authorisation active surveillance safety study using secondary data to monitor real-world safety of Spikevax (COVID-19 mRNA-1273 vaccine) in Europe – an enhanced pharmacovigilance study to provide additional evaluation of adverse events of special interest (AESI) and emerging validated safety signals in European populations and electronic database assessment of use in pregnant women

**Action:** For adoption of advice to CHMP

### 7.5.4. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 034.6

**Applicant:** Moderna Biotech Spain, S.L.

**PRAC Rapporteur:** Marie Louise Schougaard Christiansen

Scope: Third interim report for the study of monitoring safety of COVID-19 Vaccine Moderna in pregnancy: an observational study using routinely collected health data in five European countries - Post-marketing safety study for COVID-19 mRNA-1273 vaccine

**Action:** For adoption of advice to CHMP

### 7.5.5. Fenfluramine - FINTEPLA (CAP) - EMEA/H/C/003933/MEA 002.2

**Applicant:** UCB Pharma SA

**PRAC Rapporteur:** Martin Huber

Scope: MAH's response to MEA 002.1 [Progress report for study ZX008-1503: an open-label extension trial to assess the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet syndrome] as per request for supplementary information (RSI) adopted in February 2023

**Action:** For adoption of advice to CHMP

### 7.5.6. Nonacog beta pegol - REFIXIA (CAP) - EMEA/H/C/004178/LEG 006.4

**Applicant:** Novo Nordisk A/S

**PRAC Rapporteur:** Gabriele Maurer

Scope: MAH’s response to LEG 006.3 [Fourth yearly progress report for PASS NN7999-4031 (Paradigm 8): a non-interventional study in male haemophilia B patients receiving nonacog beta pegol (N9-GP) prophylaxis treatment to investigate the potential effects of polyethylene glycol (PEG) accumulation in the choroid plexus of the brain and other tissues/organs] as per request for supplementary information (RSI), adopted in March 2023

**Action:** For adoption of advice to CHMP

### 7.5.7. Tolvaptan - JINARC (CAP) - EMEA/H/C/002788/ANX 002.4

**Applicant:** Otsuka Pharmaceutical Netherlands B.V.

**PRAC Rapporteur:** Amelia Cupelli
Scope: MAH's response to ANX 002.3 [interim report for study 156-12-299: a non-interventional PASS to investigate the risks of hepatotoxicity, basal cell carcinoma and glaucoma associated with the use of Jinarc (tolvaptan). In addition, the study investigates pregnancy outcomes in patients treated with Jinarc (tolvaptan), patterns of medicinal product utilisation especially with regards to off-label use and use in patients over 50 years old as well as adverse drug reactions (ADRs) associated with long term use of Jinarc (tolvaptan) [final clinical study report (CSR) expected by: Q1/2026]] as per the request for supplementary information (RSI) adopted in February 2023

Action: For adoption of advice to CHMP

7.5.8. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 017.6

Applicant: BioNTech Manufacturing GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Third interim report for study C4591021 (former ACCESS/VAC4EU): an assessment of potential increased risk of adverse events of special interest (AESI), including myocarditis/pericarditis after being vaccinated with COVID-19 messenger ribonucleic acid (mRNA) vaccine estimating the time trend, in relation to DHPC letter dissemination, of the proportion of individuals who received real-world clinical assessments for myocarditis/pericarditis following Comirnaty (tozinameran) vaccination

Action: For adoption of advice to CHMP

7.5.9. Ulipristal acetate - ESMYA (CAP) - EMEA/H/C/002041/MEA 018.7

Applicant: Gedeon Richter Plc.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Seventh yearly progress report for study PGL14-001: a prospective, multinational, multicentre, non-interventional study to evaluate the long-term safety of Esmya (ulipristal acetate) in particular the endometrial safety and the current prescription and management patterns of Esmya (ulipristal acetate) in a long-term treatment setting

Action: For adoption of advice to CHMP

7.5.10. Venetoclax - VENCLYXTO (CAP) - EMEA/H/C/004106/MEA 002.10

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Eva Jirsová
Scope: Prospective observational study to assess the long term safety profile of venetoclax in a Swedish cohort of Chronic Lymphocytic Leukaemia (CLL) patients

Action: For adoption of advice to CHMP
7.5.11. **Voretigene neparvovec - LUXTURNA (CAP) - EMEA/H/C/004451/ANX 011**

Applicant: Novartis Europharm Limited, ATMP\(^{23}\)
PRAC Rapporteur: Gabriele Maurer
Scope: Interim report for study CLTW888A12401: a Post-Authorisation, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec

**Action:** For adoption of advice to CAT and CHMP

7.6. **Others**

None

7.7. **New Scientific Advice**

None

7.8. **Ongoing Scientific Advice**

None

7.9. **Final Scientific Advice (Reports and Scientific Advice letters)**

None

8. **Renewals of the marketing authorisation, conditional renewal and annual reassessments**

8.1. **Annual reassessments of the marketing authorisation**

8.1.1. **Amifampridine - FIRDAPSE (CAP) - EMEA/H/C/001032/S/0075 (without RMP)**

Applicant: SERB SA
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

8.1.2. **Chenodeoxycholic acid - CHENODEOXYCHOLIC ACID LEADIANT (CAP) - EMEA/H/C/004061/S/0022 (without RMP)**

Applicant: Leadiant GmbH

\(^{23}\) Advanced therapy medicinal product
PRAC Rapporteur: Adam Przybylkowski
Scope: Annual reassessment of the marketing authorisation
Action: For adoption of advice to CHMP

### 8.1.3. Idursulfase - ELAPRASE (CAP) - EMEA/H/C/000700/S/0111 (without RMP)

Applicant: Takeda Pharmaceuticals International AG Ireland Branch
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Annual reassessment of the marketing authorisation
Action: For adoption of advice to CHMP

### 8.1.4. Tecovirimat - TEOVIRIMAT SIGA (CAP) - EMEA/H/C/005248/S/0004 (without RMP)

Applicant: SIGA Technologies Netherlands B.V.
PRAC Rapporteur: Martin Huber
Scope: Annual reassessment of the marketing authorisation
Action: For adoption of advice to CHMP

### 8.1.5. Zanamivir - DECTOVA (CAP) - EMEA/H/C/004102/S/0016 (without RMP)

Applicant: GlaxoSmithKline Trading Services Limited
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Annual reassessment of the marketing authorisation
Action: For adoption of advice to CHMP

### 8.2. Conditional renewals of the marketing authorisation

#### 8.2.1. Amivantamab - RYBREVANT (CAP) - EMEA/H/C/005454/R/0007 (without RMP)

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Gabriele Maurer
Scope: Conditional renewal of the marketing authorisation
Action: For adoption of advice to CHMP

#### 8.2.2. Ixazomib - NINLARO (CAP) - EMEA/H/C/003844/R/0043 (without RMP)

Applicant: Takeda Pharma A/S
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Conditional renewal of the marketing authorisation
Action: For adoption of advice to CHMP
### 8.2.3. Pralsetinib - GAVRETO (CAP) - EMEA/H/C/005413/R/0014 (without RMP)

- **Applicant:** Roche Registration GmbH
- **PRAC Rapporteur:** Ulla Wändel Liminga
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.2.4. Spesolimab - SPEVIGO (CAP) - EMEA/H/C/005874/R/0005 (without RMP)

- **Applicant:** Boehringer Ingelheim International GmbH
- **PRAC Rapporteur:** Nathalie Gault
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

### 8.3. Renewals of the marketing authorisation

#### 8.3.1. Apalutamide - ERLEADA (CAP) - EMEA/H/C/004452/R/0030 (with RMP)

- **Applicant:** Janssen-Cilag International N.V.
- **PRAC Rapporteur:** Tiphaine Vaillant
- **Scope:** 5-year renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

#### 8.3.2. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/R/0083 (without RMP)

- **Applicant:** Biogen Netherlands B.V.
- **PRAC Rapporteur:** Martin Huber
- **Scope:** 5-year renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

#### 8.3.3. Galcanezumab - EMGALITY (CAP) - EMEA/H/C/004648/R/0023 (with RMP)

- **Applicant:** Eli Lilly Nederland B.V.
- **PRAC Rapporteur:** Kirsti Villikka
- **Scope:** 5-year renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

#### 8.3.4. Glycopyrronium, formoterol fumarate dihydrate - BEVESPI AEROSPHERE (CAP) - EMEA/H/C/004245/R/0017 (without RMP)

- **Applicant:** AstraZeneca AB
PRAC Rapporteur: Jan Neuhauser
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

### 8.3.5. Lidocaine, prilocaine - FORTACIN (CAP) - EMEA/H/C/002693/R/0038 (without RMP)

Applicant: Recordati Ireland Ltd
PRAC Rapporteur: Maria del Pilar Rayon
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

### 8.3.6. Paclitaxel - APEALEA (CAP) - EMEA/H/C/004154/R/0017 (with RMP)

Applicant: Inceptua AB
PRAC Rapporteur: Inês Ribeiro-Vaz
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

### 8.3.7. Pegfilgrastim - FULPHILA (CAP) - EMEA/H/C/004915/R/0042 (without RMP)

Applicant: Viatris Limited
PRAC Rapporteur: Menno van der Elst
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

### 8.3.8. Radium (Ra$^{223}$) - XOFFIGO (CAP) - EMEA/H/C/002653/R/0049 (with RMP)

Applicant: Bayer AG
PRAC Rapporteur: Rugile Pilviniene
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

### 8.3.9. Ropeginterferon alfa-2b - BESREMI (CAP) - EMEA/H/C/004128/R/0031 (without RMP)

Applicant: AOP Orphan Pharmaceuticals GmbH
PRAC Rapporteur: Inês Ribeiro-Vaz
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP
8.3.10. Silodosin - SILOSOSIN RECORDATI (CAP) - EMEA/H/C/004964/R/0012 (without RMP)

Applicant: Recordati Ireland Ltd
PRAC Rapporteur: Valentina Di Giovanni
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.11. Tobramycin - VANTOBRA (CAP) - EMEA/H/C/005086/R/0009 (without RMP)

Applicant: PARI Pharma GmbH
PRAC Rapporteur: Ulla Wändel Liminga
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections
None

9.2. Ongoing or concluded pharmacovigilance inspections
Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others
None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation
None

10.2. Timing and message content in relation to Member States’ safety announcements
None
10.3. Other requests

None

10.4. Scientific Advice

None

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

11.1.1. Amino acid combinations, glucose, triglyceride combinations, with or without electrolytes, mineral compounds (NAP) - SE/H/918/02-04/II/51

Applicant(s): various
PRAC Lead: Ulla Wändel Liminga
Scope: PRAC consultation on a type II national variation addressing the potential risks associated with the formation of 'yellow globules' in the lipid emulsion need to be further assessed, given the potential seriousness of this finding as per conclusions of the PSUSA procedure (PSUSA/00010190/202112) concluded in September 2022, on request of Sweden

Action: For adoption of advice to Member States

11.2. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

Action: For information

12.1.2. Vote by proxy

None

---

24 E.g. olive oil, soya bean oil, fish oil
25 Intravenous (I.V.) application only
26 Nationally authorised product Numeta only
12.1.3. Scientific Committee Meetings – alternating face-to-face and virtual meetings schedule for 2024

*Action:* For discussion

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Coronavirus (COVID-19) pandemic - update

*Action:* For discussion

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

None

12.8. Planning and reporting

12.8.1. Marketing authorisation applications (MAA) forecast for 2023 – planning update dated Q2 2023

*Action:* For discussion

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None
12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst, Maia Uusküla

Action: For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption

12.10.5. Periodic Safety Update Reports Single Assessment (PSUSA) – proactive publication of PRAC assessment reports for COVID-19 vaccines

Action: For discussion

12.11. Signal management


PRAC lead: Menno van der Elst

Action: For discussion

12.11.2. Signal management – List of substances subject to worksharing

Action: For discussion
12.12.  **Adverse drug reactions reporting and additional reporting**

12.12.1.  **Management and reporting of adverse reactions to medicinal products**

None

12.12.2.  **Additional monitoring**

None

12.12.3.  **List of products under additional monitoring – consultation on the draft list**

*Action*: For adoption

12.13.  **EudraVigilance database**

12.13.1.  **Activities related to the confirmation of full functionality**

None


12.14.1.  **Risk management systems**

None

12.14.2.  **Tools, educational materials and effectiveness measurement of risk minimisations**

None

12.15.  **Post-authorisation safety studies (PASS)**

12.15.1.  **Post-authorisation Safety Studies – imposed PASS**

None

12.15.2.  **Post-authorisation Safety Studies – non-imposed PASS**

None
12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

12.20.1. Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines in context of thrombosis with thrombocytopenia syndrome (TTS): risk awareness and adherence - PRAC Sponsor’s critical appraisal

PRAC lead: Jean-Michel Dogné

Action: For discussion

12.20.2. Strategy on measuring the impact of pharmacovigilance – PRAC interest group (IG) Impact – revision of the process for prioritisation and follow-up of impact research, including regulatory toolbox (rev.2)

Action: For discussion
12.21. **Others**

12.21.1. **International Conference on Harmonisation (ICH) E2D(R1) guideline - Post-approval safety data management: definitions and standards for expedited reporting – update on the revision process**

**Action:** For discussion

12.21.2. **Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling – concept paper on revision of the guideline**

PRAC lead: Ulla Wändel Liminga, Eva Jirsová, Hedvig Nordeng

**Action:** For discussion

12.21.3. **Good Pharmacovigilance Practice (GVP) – mid-year update 2023**

PRAC lead: Sabine Straus

**Action:** For discussion

12.21.4. **EMA-funded study on anticonvulsants in pregnancy**

**Action:** For discussion

12.21.5. **PRAC Assessors trainings - EU NTC Learning & Development (L&D) toolkit and remuneration for training development/delivery**

PRAC lead: Martin Huber, Sabine Straus

**Action:** For discussion

13. **Any other business**
14. **Explanatory notes**

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

**EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures**

(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0)

**Signals assessment and prioritisation**

(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks.

The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event. The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

**Risk Management Plans (RMPs)**

(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

**Assessment of Periodic Safety Update Reports (PSURs)**

(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine’s authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

**Post-authorisation Safety Studies (PASS)**

(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

**Product related pharmacovigilance inspections**

(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu](http://www.ema.europa.eu/)